Host-directed treatments for tuberculous meningitis: A multi-platform approach across mouse and human models

Host-directed treatments for tuberculous meningitis: A multi-platform approach across mouse and human models | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Article Host-directed treatments for tuberculous meningitis: A multi-platform approach across mouse and human models Sanjay Jain, Carlos Ruiz Gonzalez, Medha Singh, Yuderleys Masias Leon, and 17 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-8694483/v1 This work is licensed under a CC BY 4.0 License Status: Under Review Version 1 posted You are reading this latest preprint version Abstract Tuberculous meningitis (TB meningitis) is a major cause of death and neurological deficit despite recommended antibiotic and corticosteroid treatments, primarily due to dysregulated neuroinflammation. Here, we investigate a diverse panel of 12 immunomodulatory drugs as host-directed treatments (HDTs) for TB meningitis utilizing a cross-species framework comprising studies in a mouse model of TB meningitis with clinical endpoints, and parallel mechanistic studies in a newly developed immune-vascularized human brain organoid model of TB meningitis and peripheral blood mononuclear cells (PBMCs) from patients with TB meningitis. We identify new HDTs that outperform the current standard of care by reducing mortality and neurological deficits in mice via suppression of neuroinflammation. Importantly, these HDTs significantly reduce microglial activation in Mycobacterium tuberculosis -infected human brain organoids and attenuate proinflammatory cytokines, particularly IFNγ within CD4 + T-cells in patient-derived PBMCs. These findings highlight the potential of targeted HDTs to improve outcomes in TB meningitis and warrant clinical investigation. Health sciences/Medical research/Translational research Health sciences/Pathogenesis/Infection Health sciences/Medical research/Experimental models of disease Figures Figure 1 Figure 2 Figure 3 Figure 4 Figure 5 Figure 6 INTRODUCTION Despite recent reductions in tuberculosis (TB) incidence rates, TB has once again resurged as a leading cause of mortality from a single infectious agent, surpassing coronavirus disease (COVID-19) 1 . Tuberculous meningitis (TB meningitis) is the most severe form of TB 2 . Despite appropriate antibiotic treatment, at least one of four patients with TB meningitis dies, with mortality of 67% in Asia and up to 80% in Sub-Saharan Africa 2 , 3 . Furthermore, neurological sequelae are reported in 29–51% of the surviving patients 4 , 5 . Disease severity and outcomes for TB meningitis are largely driven by a dysregulated immune response within the central nervous system (CNS) 6 – 8 . While these immune mechanisms are essential for mycobacterial control, they lead to exudative meningitis, endovasculitis, infarction, hydrocephalus, and irreversible neuronal damage. Efforts to improve patient outcomes by controlling inflammation in TB meningitis date back to 1952, with the first description of corticosteroids as host-directed treatment (HDT) 9 . Since then, numerous clinical trials have investigated this approach demonstrating that adjunctive corticosteroids result in a 25% reduction in mortality in patients with TB meningitis, although no significant benefit has been observed in reducing neurological deficits 10 . Additionally, the benefits of corticosteroids for TB meningitis in patients living with HIV (PLWH) remains unclear 11 . Importantly, and contrary to results from phase II clinical trials 12 – 15 , two recent randomized clinical trials highlight the challenges of corticosteroids for TB meningitis. Meya et al. highlight rifampin-induced hepatic clearance of corticosteroids altering their efficacy in patients with TB meningitis 16 , and Donovan et al . demonstrate no difference in mortality or neurological outcomes in genotype-stratified [leukotriene A4 hydrolase (LTA4H), leukotriene pathway] TB meningitis patients expected to benefit differentially from adjunctive corticosteroids 17 . Together, these findings underscore a critical unmet therapeutic need for developing new HDTs for TB meningitis. At least two other immunomodulatory drugs are being evaluated in clinical studies for TB meningitis. These include aspirin that modulates cyclooxygenase (COX) activity 18 and infliximab, a monoclonal antibody against TNFα 19 . The immunomodulatory imide drug (IMiD) thalidomide, which has multiple modes of action including TNFα inhibition, has also shown promise in observational studies in children 20 , but is not widely used 21 . In this study, we evaluated a diverse panel of 12 immunomodulatory drugs, representing 11 different immunomodulatory drug classes, which are either U.S. FDA-approved or in clinical trials for other indications, as potential HDTs for TB meningitis (Fig. 1 ). We employed an integrated cross-species framework that combined longitudinal preclinical studies in an established mouse model of TB meningitis utilizing clinical endpoints [mortality, neurological deficits, dynamic contrast-enhanced magnetic resonance imaging (MRI)] with parallel mechanistic studies in a newly developed 3D immune-vascularized human brain organoid model of TB meningitis and peripheral blood mononuclear cells (PBMCs) from patients with TB meningitis. Studies in the human brain organoid model and PBMCs from patients with TB meningitis allowed us to respectively assess the effect of promising immunomodulatory drugs on resident human brain immune cells (in particular microglia) and on peripheral immune cells, which infiltrate the CNS in active TB meningitis and play a critical role in the pathogenesis of TB meningitis 22 – 24 . We identified several new immunomodulatory drug classes that reduce both mortality and neurological deficits in mice compared to the current standard of care, with associated decrease in neuroinflammation. Importantly, when added to the standard, first-line TB treatment (isoniazid + rifampin + pyrazinamide), these HDTs reduced microglial activation in Mycobacterium tuberculosis -infected human brain organoids and attenuated critical proinflammatory cytokines, particularly IFNγ within CD4 + T-cells in patient-derived PBMCs. Our data strongly suggest the potential role for these immunomodulatory drugs as HDTs for TB meningitis rendering support for evaluation in clinical trials for TB meningitis. RESULTS We used an established mouse model of TB meningitis 25 – 27 , utilizing intraventricular injection with M. tuberculosis . Two weeks after infection, these mice demonstrated hallmark features of TB meningitis, including parenchymal lesions, meningeal infiltration and activated microglial and astrocyte morphology ( Fig. S1 ). Mortality and neurological deficits in the mouse model of TB meningitis Two weeks after infection, mice were randomly assigned to receive TB treatment (isoniazid) with or without one of the 12 immunomodulatory drugs or dexamethasone for two weeks at human equipotent and clinically relevant dosing for all drugs ( Table S1 ). This approach was utilized to rank order the effects of each immunomodulatory drug during the initial phase (2-weeks) of TB treatments, associated with high mortality in patients with TB meningitis, and thus the ideal time for modulating host responses 12 , 22 , 28 , 29 . Each immunomodulatory drug was administered in combination with isoniazid (TB antibiotic highly active during the initial phase of treatment) as is common for the initial evaluation of new HDTs 30 , 31 . Mortality as well as the development of neurological deficits was monitored for an additional 3 months, with the investigators blinded to the treatment assignments ( Fig. S2-S5 ). The relative risk (RR) of mortality or the development of neurological deficits was calculated for each treatment arm. Consistent with its effects in patients with TB meningitis 32 , adjunctive use of dexamethasone in mice reduced mortality ( P = 0.030; Fig. 2 a, S3), but did not reduce neurological deficits ( P = 0.195; Fig. 2 b) when compared to TB treatment alone. Therefore, the dexamethasone arm was used as the reference (control) for mortality and the TB treatment alone arm was used as the reference (control) for neurological deficits. As expected, no mortality was noted in sham controls (animals injected intraventricularly with PBS) and untreated animals had a significantly higher mortality ( P < 0.001) compared to the reference (adjunctive dexamethasone treatment) arm. Adjunctive treatment with bestatin, imatinib, roflumilast, or palacaparib led to a significant reduction in mortality compared to the reference (adjunctive dexamethasone treatment) arm ( P < 0.048). Adjunctive treatment with other HDTs were not different compared to the reference arm (Fig. 2 a), although adjunctive treatment with thalidomide, aspirin, pomalidomide, semaglutide, or navitoclax led to a significant reduction in mortality compared to the TB treatment alone arm ( P < 0.040) ( Fig. S3 ). As expected, no neurological deficits were noted in sham controls and untreated animals had more neurological deficits compared to the TB treatment alone control arm ( Fig. S5 ). Adjunctive treatment with bestatin, imatinib, roflumilast, palacaparib, thalidomide, pomalidomide, or semaglutide led to a significant reduction in neurological deficits compared to the reference (TB treatment alone) arm ( P < 0.037) (Fig. 2 b, Fig. S5 ). Overall, we identified that adjunctive use of bestatin (protease inhibitor), imatinib (tyrosine kinase inhibitor), roflumilast [phosphodiesterase-4 inhibitor (PDE-4)], or palacaparib [Poly(ADP-ribose) polymerase 1, PARP-1 inhibitor] significantly reduced both mortality (compared to the control arm, adjunctive dexamethasone) and neurological deficits (compared to the control arm, TB treatment alone). Adjunctive use of thalidomide/pomalidomide (IMiD) and semaglutide [Glucagon-like peptide-1 (GLP-1) receptor agonist] significantly reduced neurological deficits (compared to the control arm, TB treatment alone) but were no different than dexamethasone in reducing mortality. Of note, neurological deficits observed for thalidomide/pomalidomide (IMiD) arms were amongst the lowest (RR 0.73 and 0.80, respectively). Adjunctive use of aspirin (COX inhibitor) or navitoclax [B-cell lymphoma 2 (BCL-2) and B-cell lymphoma-extra-large (BCL-XL) inhibitor – proapoptotic 33 ] led to a significant reduction in mortality compared to the TB treatment alone arm ( P < 0.040) ( Fig. S3 ). Adjunctive use of infliximab (monoclonal antibody against TNFα) did not reduce mortality (compared to the control arm, adjunctive dexamethasone; or TB treatment alone arm), nor did it reduce neurological deficits (compared to the control arm, TB treatment alone). Finally, montelukast (leukotriene receptor inhibitor) paradoxically increased mortality and neurological deficits. Based on these data, we selected seven immunomodulatory drugs, bestatin, imatinib, roflumilast, palacaparib, pomalidomide (more potent than thalidomide 34 ), semaglutide, and aspirin for further evaluation. Aspirin was chosen as it reduced mortality compared to the TB treatment alone arm (although not compared to the control, adjunctive dexamethasone arm), and as it is currently being evaluated in clinical trials for TB meningitis 18 . Bactericidal activity and target engagement for the Immunomodulatory drugs Immunomodulatory drugs could directly affect M. tuberculosis killing and modulation of host responses could affect (increase or decrease) bacterial killing 35 . To address this, organs (brain, lung and spleen) from a cohort of infected mice were collected two weeks after treatment initiation. The tissues were homogenized and plated to assess bacterial burden as colony forming units (CFU). As expected, TB treatment with isoniazid (antibiotic) alone was associated with a reduction in CFU compared to untreated animals in the brain, lungs, and spleen. However, the addition of none of the 12 immunomodulatory drugs or dexamethasone, significantly altered the organ bacterial burden in the brain, nor increased dissemination to the lungs or spleen ( Fig. S6 ). Some drugs fail to achieve their effects due to inadequate tissue levels. Drug doses and their brain effects were available for aspirin 36 and montelukast 37 , and were used for the current studies. For other small molecules, Western blots were performed on mouse whole-brain lysates from the treatment cohorts ( Fig. S6 ), demonstrating pathway-appropriate modulation: semaglutide downregulated GLP-1 expression, roflumilast, imatinib, navitoclax and bestatin, respectively decreased PDE-4, PDGFRα/β, BCL2, and CD13, while palacaparib increased PARP-1 cleavage, consistent with its role in inducing apoptosis. Thalidomide and pomalidomide reduced cereblon expression. Collectively, these data confirm that these drugs engage their intended molecular targets within the brain during TB meningitis ( Fig. S7 ). Dynamic contrast-enhanced brain MRI in the mouse model of TB meningitis Next, we evaluated the effects of the seven promising HDT classes on neuroinflammation using dynamic contrast-enhanced brain MRI in a cohort of live animals, complemented by post-mortem studies 2-weeks after treatment initiation. Contrast-enhanced imaging can localize areas of local tissue inflammation due to the extravasation of intravenous contrast from inflamed (and leaky) blood vessels 38 . MRI was performed using custom-built MRI compatible biocontainment beds for imaging live animals under biosafety level-3 (BSL-3) containment ( Fig. S8 ). Dynamic contrast enhanced MRI demonstrated contrast enhancement in the periventricular region (site of infection) in infected mice, which persisted throughout the duration of the scan (20 min). No such enhancement was noted in the sham controls (injected with sterile PBS) ( Fig. S9 ). The MRI contrast signal was quantified as the area under the curve (AUC) and normalized to background levels. Delta maps were generated by digitally subtracting the pre-contrast from the post-contrast images ( Fig. S10 ). Initial studies utilized TB treatment (isoniazid) with or without one of the seven promising HDTs or dexamethasone. TB treatment alone significantly reduced the contrast enhancement compared to untreated animals ( P < 0.001), which was further reduced in the dexamethasone arm, compared to TB treatment alone ( P < 0.001) ( Fig. S11 ). Importantly, bestatin, imatinib, roflumilast, palacaparib, pomalidomide, or semaglutide ( P < 0.040) arms, but not aspirin ( P = 0.34) or montelukast (signal higher), demonstrated significant reductions in contrast enhancement compared to TB treatment alone ( Fig. 3a, c ). Similar trends were noted in studies utilizing first-line TB treatment (isoniazid + rifampin + pyrazinamide) with or without adjunctive HDTs. As expected, the first-line TB treatment was more efficacious than isoniazid alone in reducing contrast enhancement. All HDTs arms tested ( P < 0.020), except for aspirin (signal higher) and imatinib ( P = 0.186), demonstrated further and significant reductions in contrast enhancement compared to the first-line TB treatment alone ( Fig. 3b, c ). Figure 3. Dynamic gadolinium-enhanced brain MRI in the mouse model of TB meningitis. ( a ) Representative axial T1-weighted MRI images acquired post-contrast injection (left column) with corresponding delta maps (right column) performed at two weeks after treatment initiation in mice showing contrast enhancement in the periventricular region are shown. TB treatment (isoniazid) or first-line TB treatment (isoniazid + rifampin + pyrazinamide) with or without adjunctive HDT were administered at human equipotent and clinically relevant dosing. ( b ) MRI contrast signal was quantified as the area under the curve (AUC) and normalized to background levels. Delta maps were generated by digitally subtracting the pre-contrast image from the post-contrast segmented brain image. Each dot represents a single region of interest (ROI), with 3 brain ROIs drawn for each animal. The dashed line represents the median values for the TB treatment (red line) and the first-line TB treatment (burgundy line) arms. Data are presented as median and interquartile range (IQR). Statistical comparisons were made using the Mann-Whitney U test. Brain tissue inflammation in the mouse model of TB meningitis After completion of imaging, mice were sacrificed and the brains were collected. Brain tissue inflammation was measured by ionized calcium-binding adaptor molecule 1 (Iba1) immunofluorescence (percentage of area covered by positive staining). As expected, first-line TB treatment (isoniazid + rifampin + pyrazinamide) significantly reduced tissue inflammation compared to untreated animals ( P < 0.001), which was further reduced in the dexamethasone arm ( P < 0.001) (Fig. 4 ). Importantly, aspirin, bestatin, imatinib, roflumilast, palacaparib, pomalidomide, or semaglutide ( P < 0.002) arms demonstrated further significant reductions in tissue inflammation, compared to the first-line TB treatment alone arm. Similar trends in brain tissue inflammation were observed in mice receiving TB treatment (isoniazid) with or without HDTs ( Fig. S12 ). We investigated serum glial fibrillary acidic protein (GFAP) in CSF as a clinically relevant biomarker of brain injury 39 , 40 , which followed the trend noted above ( Fig. S13 ). Ex vivo immune-vascularized 3D human brain organoid model of TB meningitis To evaluate the effect of the seven promising HDT classes on human brain resident immune cells, in particular microglia, we employed a strategic investigation using M. tuberculosis -infected human microglia in an ex vivo immune-vascularized 3D human organoid model. The brain organoid was generated by differentiating human induced pluripotent stem cells (iPSCs) into multipotent forebrain neural stem and neural progenitor cells. In parallel, yolk sac-like tissues from iPSCs were used to generate mesodermal derivatives resembling early extraembryonic hemato-vascular lineages, including CD31 + endothelial cells and CD45 + hematopoietic progenitors, which further differentiated into microglia and pericyte-like cells. Both the mouse brain and human brain organoid models used in this study exhibit comparable cellular complexity, encompassing key brain-resident cell types relevant to TB meningitis pathophysiology, including microglia, endothelial cells, and pericytes which are critical for modeling infection related neuroinflammatory responses ( Fig. S14 ). Preliminary viability assays were performed using M. tuberculosis -infected human microglia to establish the ideal multiplicity of infection (MOI) and time-points after infection ( Fig. S15 ). Co-incubation of each individual HDTs with TB treatment (isoniazid) at the physiologically relevant, expected human brain tissue concentrations achieved with clinically relevant dosing, was performed ( Table S2, S3 ). TB treatment alone reduced the Iba1 expression compared to untreated controls, which was further reduced with the addition of the promising HDTs tested compared to TB treatment alone in a dose-dependent manner ( Fig. S16 ). Based on these data, we chose the physiologically relevant concentrations ( Table S3 ). Using mean fluorescence intensity (MFI) of Iba1 all promising HDT classes significantly reduced microglial activation ( P < 0.030) ( Fig. S17 ). On the contrary, montelukast increased microglial activation, and overall, these results were consistent with the mouse studies. Next, we performed studies with the brain organoid model where M. tuberculosis -infected microglia were incorporated into the assembled human brain organoids to generate a complex model comprising immune and non-immune cells and probed with multi-channel immunofluorescence ( Fig. S18 ). M. tuberculosis -infected, but untreated organoids induced strong microglial activation, marked by increased Iba1, CD11b, and TMEM119 expression ( Fig. S19 ). While the first-line TB treatment (isoniazid + rifampin + pyrazinamide) alone reduced Iba1 levels, the addition of the promising HDTs at physiologically-relevant concentrations ( Table S3 ) produced a more pronounced suppression of microglial activation (Fig. 5 , S20). Quantitative analysis confirmed significant reductions in Iba1 MFI with each HDTs compared with first-line TB treatment alone ( P < 0.021) (Fig. 5 ). Similar trends were observed in brain organoids receiving TB treatment (isoniazid) with or without HDTs ( Fig. S21, S22 ). Peripheral blood mononuclear cells from patients with TB meningitis Finally, we examined the effects of the seven promising HDT classes on peripheral immune cells, specifically PBMCs, which infiltrate the CNS and play a critical role in the pathogenesis of TB meningitis 22 – 24 . PBMCs were collected from eight patients with confirmed TB meningitis and two healthy controls. The median age was 39 years (IQR, 33–41) and 60% (n = 6) were female ( Table S4 ). Half of patients with TB meningitis were PLWH. All of them were on antiretroviral therapy and exhibited Immune Reconstitution Inflammatory Syndrome (IRIS). The other half with TB meningitis exhibited paradoxical reactions. Importantly, samples used in this study were collected during a follow-up visit, and none of the patients were receiving corticosteroids at that timepoint. The PBMCs were cultured and re-exposed to live M. tuberculosis to induce the expression of a specific mycobacterial immune response ( Fig. S23 ). After washing off the bacteria, the cells were treated with first-line TB treatment (isoniazid + rifampin + pyrazinamide), with or without HDTs at physiological and clinically relevant doses ( Table S3 ) and analyzed using multiparametric flowcytometry ( Fig. S24 ). Most of the cells recovered were CD4 + T-cells (median 32.7%, IQR 32.2–33.5%) and CD8 + T-cells (median 27.9%, IQR 26.6–29.5%), with no significant differences in the proportion of cells induced by HDT treatments ( Fig. S25 ). Flow cytometry analyses showed the induction of proinflammatory cytokines, specifically a strong IFNγ expression on CD4 + T-cells upon re-exposure to live M. tuberculosis on PBMCs from patients with TB meningitis ( Fig. 6 a ) . Adjunctive HDTs decreased both the expression and the proportion of IFNγ positive CD4 + T-cells, evaluated by the IFNγ integrated MFI (iMFI) (Fig. 6 b-d). Other proinflammatory cytokines, including IL-1β and TNFα, followed a similar trend, with decreased expression in response to adjunctive HDTs. In contrast, IL-2 and IL-10 showed minimal changes ( Fig. S26, S27 ). A similar approach was applied using PBMCs isolated from the mouse model of TB meningitis (n = 40 animals) ( Fig. S28-S30 ). Consistent with the results from human PBMCs and aligned with the brain organoid studies, adjunctive HDTs were associated with downregulation of the proinflammatory response, such as IFNγ in CD4 + T-cells ( Fig. S31 ), as well as other cytokines such as IL-1β, TNFα, and IL-4 ( Fig. S32, S33 ). DISCUSSION The treatment of TB meningitis remains challenging due to the inconsistent and suboptimal penetration of many TB antibiotics into the brain 7 , 8 , and current efforts to optimize antibiotic regimens have thus far only demonstrated partial success in clinical trials. For example, while higher doses of rifampin are being evaluated to overcome its limited CNS penetration; clinical trial data regarding efficacy remain conflicting 12 , 13 , 16 , 41 , 42 . While increasing rifampin dosing was shown to improve mortality or neurological outcomes in phase II clinical trials in adults and children respectively 12 , 13 , these benefits were not translated into improved clinical outcomes (mortality or neurological deficits) in a recent larger clinical trial 16 . Although the exact reason(s) for this lack of benefit from high-dose rifampin remain unknown, reduced corticosteroids exposure resulting from rifampin-induced hepatic clearance, has been postulated as a leading factor. Similarly, clinical studies have shown that the LTA4H genotype (leukotriene pathway) modulates intracerebral inflammation with maximal benefit of corticosteroids noted in TB meningitis patients with the hyperinflammatory TT genotype 14 , 15 . However, these benefits were again not translated into improved clinical outcomes (mortality or neurological deficits) in genotype-stratified TB meningitis patients expected to benefit differentially from adjunctive corticosteroids in a recent, larger clinical trial 17 . Together, these findings underscore a critical unmet therapeutic need for developing new HDTs that can more selectively modulate neuroinflammation without broadly suppressing protective immune responses. With this understanding, HDTs have emerged as an essential rather than optional strategy to develop new treatments for TB meningitis. Accordingly, we investigated a panel of 12 immunomodulatory drugs, representing 11 different immunomodulatory drug classes, which are either FDA-approved or in advanced clinical development for other indications, as potential adjunctive treatments to replace corticosteroids for the management of TB meningitis. Extensive studies using clinical endpoints, with longitudinal monitoring, were performed in a mouse model of TB meningitis. The mouse studies were complemented by parallel mechanistic studies to evaluate the effects of these HDTs (at expected human tissue concentrations) on both human brain resident and peripheral immune cells, in a newly developed 3D immune-vascularized brain organoid model of TB meningitis and PBMCs from patients with TB meningitis, respectively. The murine model enabled the evaluation of mortality, neurological deficits and MRI-based brain imaging that mirror key clinical trial endpoints, while also correlating these findings with post-mortem immunopathology assays, which are not feasible in humans. Human equipotent drug dosing was utilized to ensure that these findings were relevant to the clinically approved (or proposed) dosing for these immunomodulatory drugs. Human organoids comprising endogenous human neural, vascular, and immune cells, enabled direct assessment of inflammatory responses within the human brain. Because the pathogenesis of active TB meningitis involves both CNS-resident and peripheral immune mechanisms 22 – 24 , the complementary use of brain organoids and PBMCs allowed us to capture these interacting compartments and demonstrate human-relevant immunomodulatory effects. Notably, these complex 3D systems provide a human-based system to interrogate immune-vascular mechanisms underlying neuroinflammation 43 , 44 , as a non-animal-based Novel Alternative Methods or New Approach Methodologies (NAMs) with extensive human-relevant applications 45 . This cross-species multi-model analysis strengthens the translational relevance of our findings by bridging mechanistic insight with clinical applicability. To rationally prioritize candidates, we performed initial studies in an established mouse model that recapitulates the histopathological and imaging features of TB meningitis 25 – 27 . We evaluated each HDT as an adjunct to isoniazid alone, using relevant drug dosing informed by existing in vitro , preclinical, and clinical pharmacokinetic data, including evidence of brain penetration. This approach enabled meaningful rank-ordering of HDTs based on clinically-comparable outcomes, which would not be feasible with studies using the first-line TB treatment (isoniazid + rifampin + pyrazinamide), which is highly efficacious and would require an unmanageable large sample size to detect any additional therapeutic benefit 30 , 31 . Our approach also focused on modulating host responses during the initial phase (2-weeks) of TB treatments, as this period is associated with high mortality in patients with TB meningitis, and thus an ideal time for intervention 12 , 22 , 28 , 29 . The investigators were blinded to the treatment assignments for these studies. Notably, we identified several HDTs including bestatin (protease inhibitor), imatinib (tyrosine kinase inhibitor), roflumilast (PDE-4 inhibitor), or palacaparib (PARP-1 inhibitor) that reduced both mortality and neurological deficits, when compared with dexamethasone. In addition, a broader set of HDTs, thalidomide / pomalidomide (IMiDs), and semaglutide (GLP-1 receptor agonist) markedly reduced severe neurological deficits compared with our control (isoniazid); importantly, these neurological benefits were not observed with adjunctive dexamethasone, consistent with clinical data and highlighting therapeutic effects beyond the current standard of care 11 , 17 . Further validation of the therapeutic efficacy was performed in animals receiving adjunctive HDTs with the first-line TB treatment. Several HDTs preserved the immunomodulatory benefits observed when used in combination with isoniazid alone, indicating that their effects are not masked by potent antimicrobial treatment. Palacaparib, bestatin, roflumilast, and pomalidomide consistently reduced brain MRI contrast enhancement and microglial activation compared with the first-line TB treatment alone, while semaglutide and imatinib showed more modest effects. The modest additive effects of imatinib when used with the first-line TB treatment versus isoniazid alone could be explained due to the increased metabolism of imatinib when co-administered with rifampin 46 . Adjunctive use of other tyrosine kinase 47 and PDE-4 inhibitors 31 have shown to reduce pulmonary inflammation in animal models of TB, and improve lung function in patients with pulmonary TB 48 . Interestingly, pyrazinamide, an important TB drug, may also influence its effects through PARP-1 inhibition 49 . However, addition of palacaparib (PARP-1 inhibitor) to the first-line TB treatment (which includes pyrazinamide), substantially and further reduced neuroinflammation in our mouse, human brain organoid and human PBMC studies. Although, initial studies with thalidomide at a high-dose (24 mg/kg/day) demonstrated worse outcomes in children 50 , recent observational studies have shown that thalidomide at a dose of 3–5 mg/kg/day is safe and improves outcomes in children with CNS TB-related complications 20 . Thalidomide is readily available and in our mouse studies, adjunctive thalidomide at a human equipotent dosing of 3–5 mg/kg/day, was most effective in reducing neurological deficits, with mortality rates similar to dexamethasone. While adjunctive high-dose aspirin (500–1000 mg) is being used to target inflammation in TB meningitis clinical trials 51 , and we modeled using high-dose aspirin in our studies reported here, clinical evidence has been mixed, with no consistent benefit demonstrated in either children (SURE trial) or adults 52 , 53 . Similarly, although retrospective cohort studies and case series have demonstrated benefit of infliximab and montelukast as rescue therapies for paradoxical reactions or IRIS 19 , 54 , 55 , our findings show that infliximab did not reduce mortality nor improve neurological outcomes, while montelukast was the poorest-performing HDT and in some measures worsened neuroinflammatory outcomes. These findings highlight the selective pathways that may be critical for therapeutic benefit in TB meningitis, and that upfront HDT treatments may be different from treatments in later inflammatory reactions, which may not fully reflect early CNS-resident immune responses. Building on this approach, we employed human microglial cultures to test these HDTs at physiological concentrations which revealed that, except montelukast, all the tested HDTs reduced microglial activation compared with isoniazid alone, enabling selection of the most physiologically relevant dose for downstream studies. Similarly, when tested at chosen clinically achievable concentrations, all the HDTs, except montelukast, significantly suppressed Iba1 expression in M. tuberculosis -infected human microglia. Extending these observations to a more human-relevant context, we next incorporated these M. tuberculosis -infected human microglia into the human brain organoid model, enabling evaluation of HDT effects within a multicellular neural environment in combination with either isoniazid alone or first-line TB treatment. Across both treatment settings, most HDTs significantly reduced microglial activation within infected organoids, as reflected by decreased Iba1 signal, whereas montelukast again failed to confer considerable benefit. Notably, the preserved efficacy of these HDTs in organoids treated with the first-line TB treatment demonstrates that their immunomodulatory effects are not masked by potent antimicrobial activity or within complex, human brain-like tissue architectures. Finally, we used PBMCs derived from both patients with TB meningitis and the mouse model of TB meningitis to demonstrate the anti-inflammatory effects of these HDTs on the immune response to M. tuberculosis . Because corticosteroids are recommended and administered early to patients with confirmed TB meningitis, we used samples from patients in cohorts with paradoxical reactions and IRIS, obtained at a follow-up timepoint after corticosteroids were discontinued. Of note, all PLWH in this cohort were on anti-retroviral treatments for several weeks at this follow-up timepoint. These cells were re-stimulated with live M. tuberculosis and exhibited a strong IFNγ response. This system demonstrated that adjunctive HDTs at physiological doses modulated the inflammatory response in peripheral immune cells, which play a critical role both in the peripheral compartment and once they infiltrate the CNS 22 – 24 . Importantly, these findings were consistent, though not identical, between human and mouse cells, demonstrating a conserved anti-inflammatory effect despite the heterogeneities across species and highlighting the clinical relevance of these findings. Our study has some limitations. Pharmacokinetic and metabolic differences between mice and humans - particularly for drugs affected by rifampin-mediated cytochrome P450 induction that may require dosing optimization or rifampin-sparing regimens 27 , 46 , 56 – 58 . In addition, human immune-vascularized brain organoids do not capture full patient-level genetic heterogeneity, and PBMCs obtained at follow-up from a cohort exhibiting paradoxical reactions and/or IRIS may not fully reflect early CNS-resident immune responses. However, our human brain organoid studies did capture the early CNS-resident immune responses, and the effects of the HDTs were consistent with the results noted from patient- as well as mouse-derived PBMCs. Of note, mouse-derived PBMCs also reflected early immune responses. Also, the small sample size further limits the ability to perform multivariable analysis, underscoring the importance of integrating these data with animal models. Future studies expanding patient-derived brain organoids and PBMC analyses to capture genetic, immunological, and disease-stage heterogeneity, particularly during acute disease, would further improve the translational relevance and guide precision clinical trials. In conclusion, this study is one of the most comprehensive evaluations of promising HDTs across complementary experimental systems - including mouse models with clinically-relevant endpoints (mortality, neurological deficit, brain MRI), human immune-vascularized brain organoids, and patient-derived PBMCs. These approaches demonstrate that several targeted immunomodulatory drug classes outperform dexamethasone in reducing neuroinflammation, mortality risk, and neurological injury in TB meningitis. By enabling mechanism-specific modulation of pathogenic inflammation without compromising antimicrobial efficacy, these findings provide a strong translational rationale for advancing select immunomodulatory drug classes into early-intervention clinical trials to improve survival and long-term neurological outcomes. METHODS Animal studies All protocols were approved by the Johns Hopkins University Biosafety, Radiation Safety, Animal Care and Use Committees (MO19M382). Female C3HeB/FeJ mice (6–8 weeks old, Jackson Laboratory) were infected (titrated frozen stocks with ~ 6.5 log 10 CFU of M. tuberculosis H37Rv) via a burr hole (Micro-Drill Kit, Braintree Scientific Inc.) using a Hamilton syringe (Hamilton, 255 88000) and stereotaxic instrument (David KOPF Instruments, model 900, coordinates 0.6 mm dorsal to bregma, 1.2 mm lateral to middle line, and 2 mm ventral). Sham mice that received intracranial injections of sterile PBS, rather than bacteria, served as controls to distinguish the effects of the infection from those due to the intracranial injection procedure itself. All animals were housed in controlled light and temperature rooms without cross-ventilation in a BSL-3 facility with unrestricted access to both food and water. Treatments : All drugs were purchased from MedChem and were either dissolved or suspended in water per the manufacturer instructions. All drugs and antibiotics were prepared and administered daily, five days per week, except for semaglutide and infliximab, which were administered every other day and once weekly, respectively, at the indicated dose and route. The immunomodulatory drug doses were chosen to simulate clinically relevant doses for immunomodulatory effects in humans, while accounting for mouse pharmacokinetics ( Table S1 , S2 ). The 5-day-on / 2-day-off schedule is standard for treatments in the mouse models of TB to approximate continuous daily therapy while accounting for animal handling and welfare. In addition, clinical guidelines and extensive programmatic experience interpret directly observed therapy given 5 days per week as equivalent to 7-day “daily” therapy, with comparable treatment success when the total number of doses is adjusted accordingly. TB antibiotics were administered at the following doses: isoniazid (10 mg/kg/day), rifampin (10 mg/kg/day), and pyrazinamide (150 mg/kg/day). Bacterial burden was quantified in whole organs (brain, lung and spleen) as CFU following two weeks of treatments using 7H11 plates supplemented with activated charcoal. Plates were incubated at 37°C for three weeks before CFU were counted. Survival and neurological signs assessment Cohorts of animals were individually marked for identification and randomly assigned to each treatment group. Mice were evaluated each week for survival, weight changes and development of neurological signs. Evident head tilt and partial or complete unilateral or bilateral limb paralysis were considered as development of severe neurological signs. The investigators were blinded to the treatment assignments for the survival and neurological deficit studies. Dynamic gadolinium-enhanced brain MRI Multislice Fast Spin Echo T1-weighted (T1w-FSE; repetition time (TR) = 1000 ms; echo time (TE) = 11 ms; number of averages = 1; field of view (FOV) = 2 × 2 cm; matrix size = 256 × 248; slice thickness = 1 mm; number of slices = 14–16; fat saturation applied) and FLASH Dynamic Contrast-Enhanced Magnetic Resonance Imaging (FLASH DCE-MRI; TR = 100 ms; TE = 4 ms; flip angle = 25°; number of averages = 1; FOV = 2 × 2 cm; matrix size = 192 × 100; slice thickness = 1 mm; number of slices = 11; time of scan = 5 or 20 minutes, intervals of 10 seconds) were performed before and after intravenous injection of gadolinium-based contrast (Magnevist, Bayer; 0.2 mmol/kg) to assess brain changes in response to treatment. Imaging was performed using a 7T MRI system (MRS DRYMAG, MRSolutions, UK) equipped with a Quadrature 20 mm-diameter mouse head coil and custom-built animal biosafety level-3 (ABSL-3) MRI-compatible biocontainers ( Fig. S8 ). VivoQuant, Preclinical ScanTM and PowerscanTM were used for MRI data analysis. AUC were calculated for the segmented whole-brain region from dynamic MR images by summing the difference maps (post-/pre-contrast) across all experimental timepoints during the 5–20 min acquisition and normalizing by background. Delta maps were generated by digitally subtracting the pre-contrast image from the post-contrast image after manual segmentation of the whole brain. Histopathology and immunofluorescence : Mice were sacrificed two weeks after treatment initiation and organs (brain, lung and spleen) were harvested and fixed after systemic perfusion with 4% paraformaldehyde. Multiple random slides were obtained from each tissue sample, stained and digitally scanned. Slides were incubated overnight at 4°C with a primary antibody against Iba1 (Thermo Fisher MA5-36257, 1:500). After washing the sections, a secondary goat Alexa-fluor 488 antibody (Thermo Fisher, A11034, 1:100) was used to incubate the tissues for 2 h at room temperature. Sections were washed and mounted with 4',6-diamidino-2-phenylindole (DAPI, Thermo Fisher, ProLong™ Gold Antifade Mountant with DNA Stain DAPI). Leica DM6B system (Leica) confocal microscope was used at 40x resolution to image. For data analysis, ten to 15 images per sample were processed in FIJI ImageJ to determine the % area staining for Iba1. CSF and brain homogenate assays Animals were sacrificed and CSF, and brain tissue were extracted. Western blot analysis was performed on brain lysate using a standardized protocol using specific primary and secondary antibodies ( Table S5 ). The protein bands were visualized on the membranes using chemiluminescent substrates (Supersignal West Pico maximum sensitivity substrate, cat. no. 34580) and analyzed using FIJI ImageJ (NIH). Human microglia Preliminary studies were performed to determine the optimum MOI and timepoint for downstream assays ( Fig. S15 ). Cell viability was assessed using lactate dehydrogenase release assay (CyQUANT LDH Cytotoxicity Assays, cat. no. C20301). Based on the results, MOI 5 at 24 hours was selected for all subsequent studies. Human brain organoid model of TB meningitis Human iPSCs were maintained in DMEM/F12 supplemented with KnockOut Serum Replacement, FGF2, GlutaMAX, non-essential amino acids, and 2-mercaptoethanol under Johns Hopkins ISCRO approval. Neural differentiation was initiated by collagenase-mediated detachment and suspension culture, followed by dual-SMAD inhibition (Noggin, dorsomorphin, SB431542). Embryoid bodies were plated on Matrigel or laminin to generate neural rosettes, from which rosette-derived neural aggregates (RONAs) were isolated and maintained as neurospheres in Neurobasal medium. Neural rosettes were expanded into glial progenitor cells and differentiated into astrocytes using defined induction and maturation media, including CNTF, over a 4-week period. Human iPSCs were differentiated into yolk sac-like tissues using staged cytokine-driven protocols to generate macrophage-like microglial progenitors, along with endothelial and pericyte populations. Floating microglial progenitors were collected after 25 days and maintained in microglia growth medium for downstream studies 59 . M. tuberculosis -infected microglia were incorporated into the organoids containing endothelial cells and pericytes. Whole organoids were treated at the specific drug concentrations for 24 hours and then formalin fixed and stained for multiple markers ( Table S5 ). PBMCs obtained from patients with TB meningitis Human studies were approved by the NIH Institutional Review Board, and studies with de-identified samples were performed. PBMCs were collected from eight patients with confirmed TB meningitis and two healthy controls from prospective observational studies (NCT00286767, NCT02147405, NCT04052022) at the National Institutes of Health (NIH). All participants provided written informed consent. The samples were collected during a follow-up visit, and none of the patients were receiving corticosteroids at that time ( Table S4 ). One day prior to infection, PBMCs were thawed, washed and cultured in complete RPMI (cRPMI) supplemented with 10% FBS, 1 mM sodium pyruvate, and 1% non-essential amino acids at 37°C in 5% CO 2 ( Fig. S23 ). M. tuberculosis was cultured for two weeks in Middlebrook 7H9 medium. Cells suspended in the supernatant were separated and adherent cells (mainly monocytes) were infected for 4 hours at a multiplicity of infection (MOI) of 1:5 based on 10% monocyte number. After infection, bacteria were washed off, and the cells in the supernatant were returned to the culture and resuspended in cRPMI supplemented with the drugs at the indicated concentrations ( Table S3 ). After 20 hours of treatment, cells were stimulated with Cell Stimulation Cocktail (e.g., PMA/Ionomycin) together with GolgiStop/GolgiPlug (BD Biosciences) for 4 hours to block cytokine secretion. Mouse PBMCs : Peripheral blood was collected from mice two weeks after TB meningitis infection. PBMCs were isolated using HISTOPAQUE®-1077 and stored at -80°C. One day prior to infection, PBMCs were thawed and cultured in cRPMI at 37°C in 5% CO₂ ( Fig. S28 ). PBMCs were infected for 4 hours at a multiplicity of infection (MOI) of 1:5 based on 10% monocyte number. After infection, cells were washed and resuspended in cRPMI with drugs at the indicated concentrations ( Table S3 ). After 24 hours of treatment, supernatants were collected for cytokine quantification. Cells were then resuspended in medium and stimulated with Cell Stimulation Cocktail (e.g., PMA/Ionomycin) together with GolgiStop/GolgiPlug (BD Biosciences) for 4 hours to block cytokine secretion. Flow Cytometry Antibodies used for human and mouse staining are listed in Table S6 . Cells were washed in PBS and stained for viability using Fixable Viability Dye Live/Dead Blue (Invitrogen, L23105). After washing with FACS buffer (PBS + 0.5% BSA), Fc blocking was performed for 10 minutes at room temperature using Human Fc Block (BD Biosciences, 564220) or Mouse Fc Block (BD Biosciences, 553142). Surface staining was performed in 100 µL of FACS buffer using a surface antibody cocktail for 20 minutes at 4°C. Cells were then fixed and permeabilized using the Fixation/Permeabilization Solution Kit (eBioscience, 00-5521-00). Following fixation, cells were washed with Permeabilization/Wash buffer (eBioscience, 00-8333-56) and Cytofix/Cytoperm (BD Biosciences, 554714); intracellular staining was performed in 100 µL of the same buffer with an intracellular antibody cocktail for 1 hour at 4°C. After staining, cells were resuspended in FACS buffer and acquired on a 5-laser Cytek Aurora spectral flow cytometer (Bayview Immunomics Core, Johns Hopkins Bayview Campus, MD). Data were analyzed using FlowJo v11 (BD) with gating strategies shown ( Fig. S24, S29 ). High-dimensional analysis of cell phenotypes was performed using the FlowJo plugins DownSample v3 and UMAP. Integrated mean fluorescence intensity (iMFI) was calculated by multiplying the mean fluorescence intensity of each marker by the percentage of positive cells. Statistical analysis Data was analyzed using Prism 10 Version 10.1.1 (GraphPad). Bacterial burden (CFUs) are represented on a logarithmic scale (base 10) as mean ± SD and all other data are represented as median ± IQR. Comparisons were made using a single-tailed Wilcoxon, Mann-Whitney U or Chi-square test to the predefined control group. RR and 95% CI were calculated using the Katz log rank test. P values ≤ 0.05 were considered statistically significant. No sex-based analyses were performed because the study design was not explicitly set up to examine sex differences. DATA AVAILABILITY All data are available in the main text or the supplementary materials. Source data are provided with this paper. Declarations Acknowledgments We thank all the participants in the clinical studies. This work was funded by the U.S. National Institutes of Health R01-AI145435-A1, R01-AI153349, R56-AI179012-A1, R01-AI190038, and S10-OD030381-A1 to S.K.J. This research was also supported in part by the Intramural Research Program of the National Institutes of Health (D.T., M.T.S., N.H.G., M.M. and I.S.), Johns Hopkins Alzheimer's Disease Research Center (JHADRC) Faculty Award P30-AG066507 (K.L. and J-C.X.) and R01-AI152688 (Y.M-M. and W.R.B.). The contributions of the NIH authors are considered Works of the United States Government. The findings and conclusions presented in this paper are those of the author(s) and do not necessarily reflect the views of the NIH or the U.S. Department of Health and Human Services. Author contributions C.E.R-G., M.S. and S.K.J. conceptualized and designed the studies. C.E.R-G., M.S., Y.M-L. and Y.M-M. performed the in vitro studies. W.R.B. provided material support and advise for the PBMC studies. C.E.R-G., Y.M-L. and X.C. performed animal studies with help from M.S. M.O.S., S.P. and ML.S. K.L. and J-C.X. developed and provided brain organoids. D.T., M.T.S. and N.H.G. formulated and provided the IMiDs. They were also involved with the study design and analyses of these study data. C.E.R-G. and D.A. developed the imaging protocols and analyzed the MRI data. C.E.R-G., A.V-R. and F.D. designed the flow cytometry protocols and analyzed the data. R.H. provided advice on the selection of immunomodulatory drugs. M.M. and I.S. designed and developed the human cohorts and recruited / consented the human participants. They were also involved with the study design and analyses of these study data. C.E.R-G. and M.S., with support from Y.M-L., and A.V-R., analyzed all the study data. S.K.J. provided funding and supervised the project. C.E.R-G., M.S., Y.M-L. and S.K.J. wrote the manuscript with substantial input from all co-authors. Competing interests All authors declare that they have no competing interests. References Global tuberculosis report 2025 (2025) World Health Organization Dodd PJ et al (2021) The global burden of tuberculous meningitis in adults: A modelling study. PLOS Glob Public Health 1:e0000069 Stadelman AM et al (2020) Treatment Outcomes in Adult Tuberculous Meningitis: A Systematic Review and Meta-analysis. Open Forum Infect Dis 7:ofaa257 Wen L et al (2019) Clinical features, outcomes and prognostic factors of tuberculous meningitis in adults worldwide: systematic review and meta-analysis. J Neurol 266:3009–3021 Wang MG et al (2019) Treatment outcomes of tuberculous meningitis in adults: a systematic review and meta-analysis. BMC Pulm Med 19:200 Wilkinson RJ et al (2017) Tuberculous meningitis. Nat Rev Neurol 13:581–598 Jain SK et al (2018) Tuberculous meningitis: a roadmap for advancing basic and translational research. Nat Immunol 19:521–525 Donovan J et al (2025) A clinical practice guideline for tuberculous meningitis. Lancet Infect Dis Shane SJ, Clowater RA, Riley C (1952) The treatment of tuberculous meningitis with cortisone and streptomycin. Can Med Assoc J 67:13–15 Prasad K, Singh MB, Ryan H (2016) Corticosteroids for managing tuberculous meningitis. Cochrane Database Syst Rev 4:CD002244 Donovan J et al (2023) Adjunctive Dexamethasone for Tuberculous Meningitis in HIV-Positive Adults. N Engl J Med 389:1357–1367 Ruslami R et al (2013) Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. Lancet Infect Dis 13:27–35 Paradkar MS et al (2022) Randomized Clinical Trial of High-Dose Rifampicin With or Without Levofloxacin Versus Standard of Care for Pediatric Tuberculous Meningitis: The TBM-KIDS Trial. Clin Infect Dis 75:1594–1601 Tobin DM et al (2012) Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections. Cell 148:434–446 Thuong NTT et al (2017) Leukotriene A4 Hydrolase Genotype and HIV Infection Influence Intracerebral Inflammation and Survival From Tuberculous Meningitis. J Infect Dis 215:1020–1028 Meya DB et al (2025) Trial of High-Dose Oral Rifampin in Adults with Tuberculous Meningitis. N Engl J Med 393:2434–2446 Donovan J et al (2026) Genotype-stratified adjunctive dexamethasone for tuberculous meningitis in HIV-negative adults: a randomized controlled phase 3 trial. Nat Med Bhatia R et al (2025) A randomised trial to assess the efficacy of add on therapy with aspirin or clopidogrel to the standard medical therapy alone in patients with tubercular meningitis: ACT TBM. Lancet Reg Health Southeast Asia 37:100604 Manesh A et al (2023) Effectiveness of Adjunctive High-Dose Infliximab Therapy to Improve Disability-Free Survival Among Patients With Severe Central Nervous System Tuberculosis: A Matched Retrospective Cohort Study. Clin Infect Dis 77:1460–1467 van Toorn R, Solomons RS, Seddon JA, Schoeman JF (2021) Thalidomide Use for Complicated Central Nervous System Tuberculosis in Children: Insights From an Observational Cohort. Clin Infect Dis 72:e136–e145 van Toorn R et al (2021) The use of thalidomide to treat children with tuberculosis meningitis: A review. Tuberculosis (Edinb) 130:102125 Be NA, Kim KS, Bishai WR, Jain SK (2009) Pathogenesis of central nervous system tuberculosis. Curr Mol Med 9:94–99 Ma Q et al (2024) Interactions between CNS and immune cells in tuberculous meningitis. Front Immunol 15:1326859 Marais S et al (2014) Neutrophil-associated central nervous system inflammation in tuberculous meningitis immune reconstitution inflammatory syndrome. Clin Infect Dis 59:1638–1647 Ruiz-Bedoya CA et al (2022) High-dose rifampin improves bactericidal activity without increased intracerebral inflammation in animal models of tuberculous meningitis. J Clin Invest 132 Mota F et al (2022) Dynamic (18)F-Pretomanid PET imaging in animal models of TB meningitis and human studies. Nat Commun 13:7974 Chen X et al (2024) Dynamic PET reveals compartmentalized brain and lung tissue antibiotic exposures of tuberculosis drugs. Nat Commun 15:6657 Soria J et al (2019) Mortality in hospitalized patients with tuberculous meningitis. BMC Infect Dis 19:9 Jaipuriar RS et al (2019) Early Mortality among Immunocompetent Patients of Tuberculous Meningitis: A Prospective Study. Am J Trop Med Hyg 101:357–361 Bhaskar A et al (2020) Host sirtuin 2 as an immunotherapeutic target against tuberculosis. Elife 9 Subbian S et al (2011) Phosphodiesterase-4 inhibition alters gene expression and improves isoniazid-mediated clearance of Mycobacterium tuberculosis in rabbit lungs. PLoS Pathog 7:e1002262 Thwaites GE et al (2004) Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med 351:1741–1751 Singh M et al (2025) Proapoptotic Bcl-2 inhibitor as potential host directed therapy for pulmonary tuberculosis. Nat Commun 16:3003 Wang JY et al (2016) Pomalidomide mitigates neuronal loss, neuroinflammation, and behavioral impairments induced by traumatic brain injury in rat. J Neuroinflammation 13:168 Hanlon DP, Gale TF, Ferm VH (1975) Permeability of the syrian hamster placenta to manganous ions during early embryogenesis. J Reprod Fertil 44:109–112 Berk M et al (2013) Aspirin: a review of its neurobiological properties and therapeutic potential for mental illness. BMC Med 11:74 Michael J et al (2021) The Leukotriene Receptor Antagonist Montelukast Attenuates Neuroinflammation and Affects Cognition in Transgenic 5xFAD Mice. Int J Mol Sci 22 Heye AK, Culling RD, Hernandez Mdel V, Thrippleton C, M.J., Wardlaw JM (2014) Assessment of blood-brain barrier disruption using dynamic contrast-enhanced MRI. A systematic review. Neuroimage Clin 6:262–274 Baran AI et al (2023) Evaluation of cerebrospinal fluid levels for ALOX5, S100B, DEFA1, and GFAP in infectious meningitis. Med (Baltim) 102:e36463 Rohlwink UK et al (2017) Biomarkers of Cerebral Injury and Inflammation in Pediatric Tuberculous Meningitis. Clin Infect Dis 65:1298–1307 Te Brake L et al (2015) Pharmacokinetic/pharmacodynamic analysis of an intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis. Int J Antimicrob Agents 45:496–503 Heemskerk AD et al (2016) Intensified Antituberculosis Therapy in Adults with Tuberculous Meningitis. N Engl J Med 374:124–134 Kim J, Koo BK, Knoblich JA (2020) Human organoids: model systems for human biology and medicine. Nat Rev Mol Cell Biol 21:571–584 Qian X, Song H, Ming GL (2019) Brain organoids: advances, applications and challenges. Development 146 Catalizing the Development and Use of Novel Alternative Methods (2023) Advisory Committee to the Director, National Institutes of Health Bolton AE et al (2004) Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects. Cancer Chemother Pharmacol 53:102–106 Shee S et al (2025) Elimination of senescent cells with senolytic host-directed therapy reduces tuberculosis progression in mice. bioRxiv Wallis RS et al (2021) Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial. Lancet Respir Med 9:897–908 Krug S et al (2023) Inhibition of host PARP1 contributes to the anti-inflammatory and antitubercular activity of pyrazinamide. Nat Commun 14:8161 Schoeman JF et al (2004) Adjunctive thalidomide therapy for childhood tuberculous meningitis: results of a randomized study. J Child Neurol 19:250–257 Davis AG, Wilkinson RJ (2021) Aspirin in tuberculous meningitis. EClinicalMedicine 35:100871 Aslanian D, Negrerie M (1985) A Raman spectroscopic investigation of the lipid state in acetylcholine receptor-rich membranes from Torpedo marmorata. EMBO J 4:965–969 Mai NTH et al (2018) A randomised double blind placebo controlled phase 2 trial of adjunctive aspirin for tuberculous meningitis in HIV-uninfected adults. Elife 7 Marais BJ et al (2021) Use of Infliximab to Treat Paradoxical Tuberculous Meningitis Reactions. Open Forum Infect Dis 8:ofaa604 Hardwick C et al (2006) Montelukast in the treatment of HIV associated immune reconstitution disease. Sex Transm Infect 82:513–514 Calderin JM et al (2025) Pharmacokinetics of Dexamethasone in Tuberculous Meningitis. Clin Infect Dis Nassr N et al (2009) Effects of rifampicin on the pharmacokinetics of roflumilast and roflumilast N-oxide in healthy subjects. Br J Clin Pharmacol 68:580–587 Chen X et al (2026) Beyond Rifampin: Evaluating Rifapentine and Rifabutin as Alternative Treatments for TB Meningitis. J Infect Dis Fang H et al (2025), APOE genotype confers context-dependent neurovascular vulnerability in immune-vascularized human forebrain organoids. bioRxiv Additional Declarations There is NO Competing Interest. Supplementary Files 20260227Supplementarydata.docx Supplementary data Cite Share Download PDF Status: Under Review Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-8694483","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Article","associatedPublications":[],"authors":[{"id":600797322,"identity":"d419944a-cd05-4b74-b19c-0ae0ed99830c","order_by":0,"name":"Sanjay Jain","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA7ElEQVRIiWNgGAWjYJACAyBmBkLGBwwMB0jTwmxAtBYYYJMgSot8+9kDBT/bGNj523mPVfyouRPN38B87OMXfI46k5dg2NvGwCxxmC/tZs+xZ7kzDrAlz5bBp4Uhx8CAF6iF4TCP2W3GhsO5Gxh4jJkl8Dms/42B4V+gFnmglmKitDDcyDEwBtliANTCDNPC+AGfw268MTCWOSfBbHiYx1iy59jh3BmH2ZKZ8Vki359jZvimzCZZ7vwZww8/ag7n9rc3H2b8gU8PMDoMGNkkkhF8oBXMPPi1MD9g+MNghyJEyJZRMApGwSgYWQAAYHNIUxQbqXsAAAAASUVORK5CYII=","orcid":"https://orcid.org/0000-0001-9620-7070","institution":"Cincinnati Children's Hospital Medical Center","correspondingAuthor":true,"prefix":"","firstName":"Sanjay","middleName":"","lastName":"Jain","suffix":""},{"id":600797323,"identity":"ace721c9-0a9c-442f-9471-6547b5e75ad2","order_by":1,"name":"Carlos Ruiz Gonzalez","email":"","orcid":"","institution":"Cincinnati Children’s Hospital Medical Center","correspondingAuthor":false,"prefix":"","firstName":"Carlos","middleName":"Ruiz","lastName":"Gonzalez","suffix":""},{"id":600797324,"identity":"74f492cb-857d-4150-8730-998d56a3c706","order_by":2,"name":"Medha Singh","email":"","orcid":"","institution":"Cincinnati Children’s Hospital Medical Center","correspondingAuthor":false,"prefix":"","firstName":"Medha","middleName":"","lastName":"Singh","suffix":""},{"id":600797325,"identity":"5e1d1b07-3fed-493e-a30f-9f55d93cab95","order_by":3,"name":"Yuderleys Masias Leon","email":"","orcid":"","institution":"Cincinnati Children’s Hospital Medical Center","correspondingAuthor":false,"prefix":"","firstName":"Yuderleys","middleName":"Masias","lastName":"Leon","suffix":""},{"id":600797326,"identity":"4aae61dd-e199-4e46-bb95-32ae02879a95","order_by":4,"name":"Xueyi Chen","email":"","orcid":"https://orcid.org/0000-0003-1574-7759","institution":"Johns Hopkins University School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Xueyi","middleName":"","lastName":"Chen","suffix":""},{"id":600797327,"identity":"89a1f11f-f6b7-4152-b7d8-e0788f235df6","order_by":5,"name":"Mona Sarhan","email":"","orcid":"","institution":"Cincinnati Children’s Hospital Medical Center","correspondingAuthor":false,"prefix":"","firstName":"Mona","middleName":"","lastName":"Sarhan","suffix":""},{"id":600797328,"identity":"121322a1-5481-47a7-a008-cdbca128940a","order_by":6,"name":"Yazmin Martinez-Martinez","email":"","orcid":"https://orcid.org/0009-0009-9568-8998","institution":"Johns Hopkins University School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Yazmin","middleName":"","lastName":"Martinez-Martinez","suffix":""},{"id":600797329,"identity":"68970e01-894f-4501-be60-994eeb635cff","order_by":7,"name":"Shruti Patel","email":"","orcid":"","institution":"Johns Hopkins University School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Shruti","middleName":"","lastName":"Patel","suffix":""},{"id":600797330,"identity":"b5bd7420-4d17-4c7a-9e40-296eb32f0e05","order_by":8,"name":"Madelynn Shambles","email":"","orcid":"","institution":"Johns Hopkins University School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Madelynn","middleName":"","lastName":"Shambles","suffix":""},{"id":600797331,"identity":"374158b7-faeb-47e4-9455-0659498401ce","order_by":9,"name":"Andres Villabona-Rueda","email":"","orcid":"","institution":"Miller School of Medicine, University of Miami","correspondingAuthor":false,"prefix":"","firstName":"Andres","middleName":"","lastName":"Villabona-Rueda","suffix":""},{"id":600797332,"identity":"38ace58a-e989-4259-9c67-d2ddc6509cbe","order_by":10,"name":"Kadia Lissit","email":"","orcid":"","institution":"Johns Hopkins University School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Kadia","middleName":"","lastName":"Lissit","suffix":""},{"id":600797333,"identity":"075ba767-ab9f-45bb-8e05-bf2fd8fee7a4","order_by":11,"name":"David Tweedie","email":"","orcid":"","institution":"National Institutes of Health","correspondingAuthor":false,"prefix":"","firstName":"David","middleName":"","lastName":"Tweedie","suffix":""},{"id":600797334,"identity":"ddfb79d6-a954-431c-bde1-eca9b6e8c501","order_by":12,"name":"Michael Scerba","email":"","orcid":"","institution":"National Institutes of Health","correspondingAuthor":false,"prefix":"","firstName":"Michael","middleName":"","lastName":"Scerba","suffix":""},{"id":600797335,"identity":"0e513d23-00a6-4536-a9a8-1eaa902f8d81","order_by":13,"name":"William Bishai","email":"","orcid":"https://orcid.org/0000-0002-8734-4118","institution":"Johns Hopkins University, School of Medicine, Department of Medicine, Center for Tuberculosis Research, Baltimore","correspondingAuthor":false,"prefix":"","firstName":"William","middleName":"","lastName":"Bishai","suffix":""},{"id":600797336,"identity":"4a42b87d-590b-4577-8bf5-cd01347325d0","order_by":14,"name":"Dmitri Artemov","email":"","orcid":"","institution":"Johns Hopkins University School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Dmitri","middleName":"","lastName":"Artemov","suffix":""},{"id":600797337,"identity":"c93d4705-aa54-4ddf-9f76-49fe7c2557ed","order_by":15,"name":"Jinchong Xu","email":"","orcid":"https://orcid.org/0000-0002-9519-9029","institution":"Johns Hopkins Medicine","correspondingAuthor":false,"prefix":"","firstName":"Jinchong","middleName":"","lastName":"Xu","suffix":""},{"id":600797338,"identity":"954cfa0f-90e6-41d3-91a8-b5d90e33b2ec","order_by":16,"name":"Franco D’Alessio","email":"","orcid":"","institution":"Miller School of Medicine, University of Miami","correspondingAuthor":false,"prefix":"","firstName":"Franco","middleName":"","lastName":"D’Alessio","suffix":""},{"id":600797339,"identity":"a7ce5bf5-da55-4618-b5df-965dd569260b","order_by":17,"name":"Richard Hafner","email":"","orcid":"","institution":"National Institutes of Health","correspondingAuthor":false,"prefix":"","firstName":"Richard","middleName":"","lastName":"Hafner","suffix":""},{"id":600797340,"identity":"f423228e-9ea1-47ca-9c8a-7fc65a36e002","order_by":18,"name":"Nigel Greig","email":"","orcid":"","institution":"NIA","correspondingAuthor":false,"prefix":"","firstName":"Nigel","middleName":"","lastName":"Greig","suffix":""},{"id":600797341,"identity":"74476cf2-a142-41ed-a29d-872d319a5c76","order_by":19,"name":"Maura Manion","email":"","orcid":"","institution":"National Institute of Allergy and Infectious Diseases","correspondingAuthor":false,"prefix":"","firstName":"Maura","middleName":"","lastName":"Manion","suffix":""},{"id":600797342,"identity":"ddf7a817-7b5b-49c6-b0ec-f5f419a35ede","order_by":20,"name":"Irini Sereti","email":"","orcid":"https://orcid.org/0000-0002-0076-0224","institution":"NIAID","correspondingAuthor":false,"prefix":"","firstName":"Irini","middleName":"","lastName":"Sereti","suffix":""}],"badges":[],"createdAt":"2026-01-25 19:20:14","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-8694483/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-8694483/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":104404207,"identity":"848deb0d-9d98-4c9c-803a-5dee36e00e57","added_by":"auto","created_at":"2026-03-11 12:19:50","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":2102575,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eModel systems.\u0026nbsp;\u003c/strong\u003eWe evaluated a panel of 12 immunomodulatory drugs, representing 11 different immunomodulatory drug classes, which are U.S. FDA-approved or in clinical trials for other indications, targeting diverse host-immune pathways, as potential HDTs for TB meningitis. Multiple model systems were utilized, including an established mouse model of TB meningitis using clinical endpoints [mortality, neurological deficits, dynamic contrast-enhanced magnetic resonance imaging (MRI)]; a newly developed 3D immune-vascularized human brain organoid model of TB meningitis, and human-derived peripheral blood mononuclear cells (PBMCs) from patients with TB meningitis. COX, cyclooxygenase; PARP-1, Poly(ADP-ribose) polymerase 1; BCL-2, B-cell lymphoma 2; BCL-XL, B-cell lymphoma-extra-large); GLP-1, Glucagon-like peptide-1. Created in BioRender. Masias, Y. (2026) https://biorender.com/mpr1v9l\u003c/p\u003e","description":"","filename":"1.png","url":"https://assets-eu.researchsquare.com/files/rs-8694483/v1/113c245e2b72c94b5e701e9f.png"},{"id":104180346,"identity":"43082fa8-337d-4159-b88b-dc52413976f9","added_by":"auto","created_at":"2026-03-08 17:13:00","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":1481813,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eMortality and neurological deficits in the mouse model of TB meningitis.\u003c/strong\u003e Two weeks after an intraventricular infection with \u003cem\u003eM. tuberculosis\u003c/em\u003e, mice were randomly assigned to receive TB treatment (isoniazid) with or without adjunctive host-directed treatment (HDT) for two weeks at human equipotent and clinically relevant dosing for each drug. Mortality and the development of neurological deficits were monitored for 3 months after treatment discontinuation, with the investigators blinded to treatment assignments. (\u003cstrong\u003ea\u003c/strong\u003e) Relative risk (RR) of mortality and 95% confidence intervals (CI) using TB treatment with adjunctive dexamethasone as the reference (control) arm, based on clinical evidence that adjunctive dexamethasone reduces mortality in TB meningitis. (\u003cstrong\u003eb\u003c/strong\u003e)\u003cstrong\u003e \u003c/strong\u003eRR of developing neurological deficits (head tilt or limb paralysis) and 95% confidence intervals (CI) using TB treatment as the reference (control) arm, based on clinical evidence that adjunctive dexamethasone does not reduce the development of neurological deficits in TB meningitis. Animal numbers are indicated for each treatment arm. 95% CI and statistical significance were assessed using the Katz log-rank test and the Chi-square test.\u003c/p\u003e","description":"","filename":"2.png","url":"https://assets-eu.researchsquare.com/files/rs-8694483/v1/8dd67996dc714bde14568a7a.png"},{"id":104180349,"identity":"1a71678d-ed54-4c17-a90f-5f23c104a3f1","added_by":"auto","created_at":"2026-03-08 17:13:00","extension":"png","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":2773788,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eDynamic gadolinium-enhanced brain MRI in the mouse model of TB meningitis.\u003c/strong\u003e (\u003cstrong\u003ea\u003c/strong\u003e) Representative axial T1-weighted MRI images acquired post-contrast injection (left column) with corresponding delta maps (right column) performed at two weeks after treatment initiation in mice showing contrast enhancement in the periventricular region are shown. TB treatment (isoniazid) or first-line TB treatment (isoniazid + rifampin + pyrazinamide) with or without adjunctive HDT were administered at human equipotent and clinically relevant dosing. (\u003cstrong\u003eb\u003c/strong\u003e) MRI contrast signal was quantified as the area under the curve (AUC) and normalized to background levels. Delta maps were generated by digitally subtracting the pre-contrast image from the post-contrast segmented brain image. Each dot represents a single region of interest (ROI), with 3 brain ROIs drawn for each animal. The dashed line represents the median values for the TB treatment (red line) and the first-line TB treatment (burgundy line) arms. Data are presented as median and interquartile range (IQR). Statistical comparisons were made using the Mann-Whitney U test.\u003c/p\u003e","description":"","filename":"3.png","url":"https://assets-eu.researchsquare.com/files/rs-8694483/v1/4707d59b5956c09c357ac708.png"},{"id":104403762,"identity":"8509bda8-fce8-4824-9adc-a28518eea69d","added_by":"auto","created_at":"2026-03-11 12:18:59","extension":"png","order_by":4,"title":"Figure 4","display":"","copyAsset":false,"role":"figure","size":3668875,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eBrain tissue studies in the mouse model of TB meningitis.\u003c/strong\u003e Brain tissues were collected, fixed, and stained two weeks after treatment initiation in mice receiving first-line TB treatment (isoniazid + rifampin + pyrazinamide), with or without adjunctive HDTs. (\u003cstrong\u003ea\u003c/strong\u003e) Representative immunofluorescence images are shown. Microglia are labeled with ionized calcium-binding adaptor molecule 1 (Iba1, green), and nuclei are counterstained with 4',6-diamidino-2-phenylindole (DAPI, blue) (40x magnification, scale bar = 20 μm). (\u003cstrong\u003eb\u003c/strong\u003e) Quantification of Iba1+ (percentage of area covered by positive staining) for each treatmentarm. Each dot represents a single brain section. The dashed line represents the median value for the first-line TB treatment arm. Data are presented as median and IQR. Statistical comparisons were performed using the Mann-Whitney U test.\u003c/p\u003e","description":"","filename":"4.png","url":"https://assets-eu.researchsquare.com/files/rs-8694483/v1/fde2d0f4782a5388db8a9e66.png"},{"id":104180351,"identity":"6546bcc7-775a-4d3d-a661-efecc1a19285","added_by":"auto","created_at":"2026-03-08 17:13:01","extension":"png","order_by":5,"title":"Figure 5","display":"","copyAsset":false,"role":"figure","size":3177839,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eHuman brain organoid model of TB meningitis.\u003c/strong\u003e\u0026nbsp;(\u003cstrong\u003ea\u003c/strong\u003e) Human immune-vascularized 3D brain organoids were developed by differentiating human induced pluripotent stem cells (iPSCs) into neural cells and mesodermal derivatives, including endothelial cells and CD45\u003csup\u003e+\u003c/sup\u003e\u0026nbsp;hematopoietic progenitors. The mesodermal derivatives were further differentiated into microglia and pericytes. Microglia were infected with\u0026nbsp;\u003cem\u003eM. tuberculosis\u003c/em\u003e\u0026nbsp;and incorporated into the assembled organoids. (\u003cstrong\u003eb\u003c/strong\u003e) Optical microscopy showing the brain organoid before (top left) and after (bottom left) the incorporation of\u0026nbsp;\u003cem\u003eM. tuberculosis\u003c/em\u003e-infected microglia. Activated microglia (Iba1, green and DAPI for nuclei, blue) are noted in the organoid by confocal microscopy (middle and right panels) (5x magnification, scale bar = 50 μm). (\u003cstrong\u003ec\u003c/strong\u003e) Representative Iba1 immunofluorescence and merged DAPI + Iba1 images from\u0026nbsp;\u003cem\u003eM. tuberculosis\u003c/em\u003e-infected brain organoids after treatment with first-line TB treatment (isoniazid + rifampin + pyrazinamide), with or without adjunctive HDTs (5x magnification, scale bar = 50 μm). (\u003cstrong\u003ed\u003c/strong\u003e) Quantification of Iba1 mean fluorescence intensity (MFI) in organoids. The dashed line represents the median value for the first-line TB treatment group. Each dot represents a single brain organoid section, with at least 3 organoids per group. Data are presented as median and IQR. Statistical comparisons were made using the Mann-Whitney U test. Panel a was created in BioRender. Masias, Y. (2026) https://BioRender.com/jpy801h\u003c/p\u003e","description":"","filename":"5.png","url":"https://assets-eu.researchsquare.com/files/rs-8694483/v1/67659c4da8a684b1a0e854f4.png"},{"id":104404230,"identity":"e5f40f34-82be-4485-96d1-72b806abdddd","added_by":"auto","created_at":"2026-03-11 12:19:53","extension":"png","order_by":6,"title":"Figure 6","display":"","copyAsset":false,"role":"figure","size":2164619,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eEffect of HDTs on PBMCs during TB meningitis. \u003c/strong\u003eThe effect of HDTs on immune cells that would potentially infiltrate the central nervous system during TB meningitis was evaluated using PBMCs from patients with TB meningitis (n = 8 patients and n = 2 healthy controls). PBMCs were isolated through a density gradient protocol, stimulated through exposure to live \u003cem\u003eM. tuberculosis\u003c/em\u003e. (\u003cstrong\u003ea\u003c/strong\u003e) Differences between IFNγ responses of CD4+ T-cells from patients with TB meningitis and healthy controls is shown as contour and\u003cstrong\u003e \u003c/strong\u003ehistogram plots. PBMCs were co-incubated with first-line TB treatment (isoniazid + rifampin + pyrazinamide) with or without HDTs. (\u003cstrong\u003eb\u003c/strong\u003e) Differences between IFNγ responses of CD4+ T-cells treated with first-line TB treatment with and without adjunctive dexamethasone is shown as density and histogram plots. (\u003cstrong\u003ec\u003c/strong\u003e) Histograms illustrating the effect of adding each HDTs to the first-line TB treatment on IFNγ responses of CD4+ T-cells from patients with TB meningitis. (\u003cstrong\u003ed\u003c/strong\u003e) Quantification of the IFNγ response as integrated Mean Fluorescence Intensity (iMFI) of CD4+ T-cells from patients with TB meningitis (n = 8 participants). The dashed line represents the median value for the first-line TB treatment group. Each dot represents a single patient. Data are represented as median and IQR. Statistical comparisons were made using the Wilcoxon test. PLWH, patients living with HIV.\u003c/p\u003e","description":"","filename":"6.png","url":"https://assets-eu.researchsquare.com/files/rs-8694483/v1/1577bf184ab225d2bbe59117.png"},{"id":104808323,"identity":"d188d64f-56b4-4ba9-a711-f68825c04a57","added_by":"auto","created_at":"2026-03-17 12:35:58","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":19722699,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-8694483/v1/f8ab4829-0886-4252-b88e-c437ffe53858.pdf"},{"id":104404766,"identity":"3207b77c-66e0-420e-a06d-08c2ad13b07c","added_by":"auto","created_at":"2026-03-11 12:21:02","extension":"docx","order_by":1,"title":"","display":"","copyAsset":false,"role":"supplement","size":9769170,"visible":true,"origin":"","legend":"Supplementary data","description":"","filename":"20260227Supplementarydata.docx","url":"https://assets-eu.researchsquare.com/files/rs-8694483/v1/dfee7c6601412eb2969b82f0.docx"}],"financialInterests":"There is \u003cb\u003eNO\u003c/b\u003e Competing Interest.","formattedTitle":"Host-directed treatments for tuberculous meningitis: A multi-platform approach across mouse and human models","fulltext":[{"header":"INTRODUCTION","content":"\u003cp\u003eDespite recent reductions in tuberculosis (TB) incidence rates, TB has once again resurged as a leading cause of mortality from a single infectious agent, surpassing coronavirus disease (COVID-19)\u003csup\u003e\u003cb\u003e\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e\u003c/b\u003e\u003c/sup\u003e. Tuberculous meningitis (TB meningitis) is the most severe form of TB\u003csup\u003e2\u003c/sup\u003e. Despite appropriate antibiotic treatment, at least one of four patients with TB meningitis dies, with mortality of 67% in Asia and up to 80% in Sub-Saharan Africa\u003csup\u003e\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e,\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e\u003c/sup\u003e. Furthermore, neurological sequelae are reported in 29\u0026ndash;51% of the surviving patients\u003csup\u003e\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e,\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eDisease severity and outcomes for TB meningitis are largely driven by a dysregulated immune response within the central nervous system (CNS)\u003csup\u003e\u003cspan additionalcitationids=\"CR7\" citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e\u003c/sup\u003e. While these immune mechanisms are essential for mycobacterial control, they lead to exudative meningitis, endovasculitis, infarction, hydrocephalus, and irreversible neuronal damage. Efforts to improve patient outcomes by controlling inflammation in TB meningitis date back to 1952, with the first description of corticosteroids as host-directed treatment (HDT)\u003csup\u003e\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e\u003c/sup\u003e. Since then, numerous clinical trials have investigated this approach demonstrating that adjunctive corticosteroids result in a 25% reduction in mortality in patients with TB meningitis, although no significant benefit has been observed in reducing neurological deficits\u003csup\u003e\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e\u003c/sup\u003e. Additionally, the benefits of corticosteroids for TB meningitis in patients living with HIV (PLWH) remains unclear\u003csup\u003e\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e\u003c/sup\u003e. Importantly, and contrary to results from phase II clinical trials\u003csup\u003e\u003cspan additionalcitationids=\"CR13 CR14\" citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e\u003c/sup\u003e, two recent randomized clinical trials highlight the challenges of corticosteroids for TB meningitis. Meya \u003cem\u003eet al.\u003c/em\u003e highlight rifampin-induced hepatic clearance of corticosteroids altering their efficacy in patients with TB meningitis\u003csup\u003e\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e\u003c/sup\u003e, and Donovan \u003cem\u003eet al\u003c/em\u003e. demonstrate no difference in mortality or neurological outcomes in genotype-stratified [leukotriene A4 hydrolase (LTA4H), leukotriene pathway] TB meningitis patients expected to benefit differentially from adjunctive corticosteroids\u003csup\u003e\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e\u003c/sup\u003e. Together, these findings underscore a critical unmet therapeutic need for developing new HDTs for TB meningitis.\u003c/p\u003e \u003cp\u003eAt least two other immunomodulatory drugs are being evaluated in clinical studies for TB meningitis. These include aspirin that modulates cyclooxygenase (COX) activity\u003csup\u003e\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e\u003c/sup\u003e and infliximab, a monoclonal antibody against TNFα\u003csup\u003e\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e\u003c/sup\u003e. The immunomodulatory imide drug (IMiD) thalidomide, which has multiple modes of action including TNFα inhibition, has also shown promise in observational studies in children\u003csup\u003e\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e\u003c/sup\u003e, but is not widely used\u003csup\u003e\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eIn this study, we evaluated a diverse panel of 12 immunomodulatory drugs, representing 11 different immunomodulatory drug classes, which are either U.S. FDA-approved or in clinical trials for other indications, as potential HDTs for TB meningitis (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003e). We employed an integrated cross-species framework that combined longitudinal preclinical studies in an established mouse model of TB meningitis utilizing clinical endpoints [mortality, neurological deficits, dynamic contrast-enhanced magnetic resonance imaging (MRI)] with parallel mechanistic studies in a newly developed 3D immune-vascularized human brain organoid model of TB meningitis and peripheral blood mononuclear cells (PBMCs) from patients with TB meningitis. Studies in the human brain organoid model and PBMCs from patients with TB meningitis allowed us to respectively assess the effect of promising immunomodulatory drugs on resident human brain immune cells (in particular microglia) and on peripheral immune cells, which infiltrate the CNS in active TB meningitis and play a critical role in the pathogenesis of TB meningitis\u003csup\u003e\u003cspan additionalcitationids=\"CR23\" citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e\u003c/sup\u003e. We identified several new immunomodulatory drug classes that reduce both mortality and neurological deficits in mice compared to the current standard of care, with associated decrease in neuroinflammation. Importantly, when added to the standard, first-line TB treatment (isoniazid\u0026thinsp;+\u0026thinsp;rifampin\u0026thinsp;+\u0026thinsp;pyrazinamide), these HDTs reduced microglial activation in \u003cem\u003eMycobacterium tuberculosis\u003c/em\u003e-infected human brain organoids and attenuated critical proinflammatory cytokines, particularly IFNγ within CD4\u0026thinsp;+\u0026thinsp;T-cells in patient-derived PBMCs. Our data strongly suggest the potential role for these immunomodulatory drugs as HDTs for TB meningitis rendering support for evaluation in clinical trials for TB meningitis.\u003c/p\u003e"},{"header":"RESULTS","content":"\u003cp\u003eWe used an established mouse model of TB meningitis\u003csup\u003e\u003cspan additionalcitationids=\"CR26\" citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e\u003c/sup\u003e, utilizing intraventricular injection with \u003cem\u003eM. tuberculosis\u003c/em\u003e. Two weeks after infection, these mice demonstrated hallmark features of TB meningitis, including parenchymal lesions, meningeal infiltration and activated microglial and astrocyte morphology (\u003cb\u003eFig. \u003cspan refid=\"MOESM1\" class=\"InternalRef\"\u003eS1\u003c/span\u003e\u003c/b\u003e).\u003c/p\u003e \u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003eMortality and neurological deficits in the mouse model of TB meningitis\u003c/h2\u003e \u003cp\u003eTwo weeks after infection, mice were randomly assigned to receive TB treatment (isoniazid) with or without one of the 12 immunomodulatory drugs or dexamethasone for two weeks at human equipotent and clinically relevant dosing for all drugs (\u003cb\u003eTable \u003cspan refid=\"MOESM1\" class=\"InternalRef\"\u003eS1\u003c/span\u003e\u003c/b\u003e). This approach was utilized to rank order the effects of each immunomodulatory drug during the initial phase (2-weeks) of TB treatments, associated with high mortality in patients with TB meningitis, and thus the ideal time for modulating host responses\u003csup\u003e\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e,\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e,\u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e,\u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e\u003c/sup\u003e. Each immunomodulatory drug was administered in combination with isoniazid (TB antibiotic highly active during the initial phase of treatment) as is common for the initial evaluation of new HDTs\u003csup\u003e\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e,\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e\u003c/sup\u003e. Mortality as well as the development of neurological deficits was monitored for an additional 3 months, with the investigators blinded to the treatment assignments (\u003cb\u003eFig. S2-S5\u003c/b\u003e). The relative risk (RR) of mortality or the development of neurological deficits was calculated for each treatment arm. Consistent with its effects in patients with TB meningitis\u003csup\u003e\u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e\u003c/sup\u003e, adjunctive use of dexamethasone in mice reduced mortality (\u003cem\u003eP\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.030; Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003ea, S3), but did not reduce neurological deficits (\u003cem\u003eP\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.195; Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eb) when compared to TB treatment alone. Therefore, the dexamethasone arm was used as the reference (control) for mortality and the TB treatment alone arm was used as the reference (control) for neurological deficits.\u003c/p\u003e \u003cp\u003eAs expected, no mortality was noted in sham controls (animals injected intraventricularly with PBS) and untreated animals had a significantly higher mortality (\u003cem\u003eP\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.001) compared to the reference (adjunctive dexamethasone treatment) arm. Adjunctive treatment with bestatin, imatinib, roflumilast, or palacaparib led to a significant reduction in mortality compared to the reference (adjunctive dexamethasone treatment) arm (\u003cem\u003eP\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.048). Adjunctive treatment with other HDTs were not different compared to the reference arm (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003ea), although adjunctive treatment with thalidomide, aspirin, pomalidomide, semaglutide, or navitoclax led to a significant reduction in mortality compared to the TB treatment alone arm (\u003cem\u003eP\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.040) (\u003cb\u003eFig. S3\u003c/b\u003e).\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eAs expected, no neurological deficits were noted in sham controls and untreated animals had more neurological deficits compared to the TB treatment alone control arm (\u003cb\u003eFig. S5\u003c/b\u003e). Adjunctive treatment with bestatin, imatinib, roflumilast, palacaparib, thalidomide, pomalidomide, or semaglutide led to a significant reduction in neurological deficits compared to the reference (TB treatment alone) arm (\u003cem\u003eP\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.037) (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eb, \u003cb\u003eFig. S5\u003c/b\u003e).\u003c/p\u003e \u003cp\u003eOverall, we identified that adjunctive use of bestatin (protease inhibitor), imatinib (tyrosine kinase inhibitor), roflumilast [phosphodiesterase-4 inhibitor (PDE-4)], or palacaparib [Poly(ADP-ribose) polymerase 1, PARP-1 inhibitor] significantly reduced both mortality (compared to the control arm, adjunctive dexamethasone) and neurological deficits (compared to the control arm, TB treatment alone). Adjunctive use of thalidomide/pomalidomide (IMiD) and semaglutide [Glucagon-like peptide-1 (GLP-1) receptor agonist] significantly reduced neurological deficits (compared to the control arm, TB treatment alone) but were no different than dexamethasone in reducing mortality. Of note, neurological deficits observed for thalidomide/pomalidomide (IMiD) arms were amongst the lowest (RR 0.73 and 0.80, respectively). Adjunctive use of aspirin (COX inhibitor) or navitoclax [B-cell lymphoma 2 (BCL-2) and B-cell lymphoma-extra-large (BCL-XL) inhibitor \u0026ndash; proapoptotic\u003csup\u003e\u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e33\u003c/span\u003e\u003c/sup\u003e] led to a significant reduction in mortality compared to the TB treatment alone arm (\u003cem\u003eP\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.040) (\u003cb\u003eFig. S3\u003c/b\u003e). Adjunctive use of infliximab (monoclonal antibody against TNFα) did not reduce mortality (compared to the control arm, adjunctive dexamethasone; or TB treatment alone arm), nor did it reduce neurological deficits (compared to the control arm, TB treatment alone). Finally, montelukast (leukotriene receptor inhibitor) paradoxically increased mortality and neurological deficits. Based on these data, we selected seven immunomodulatory drugs, bestatin, imatinib, roflumilast, palacaparib, pomalidomide (more potent than thalidomide\u003csup\u003e\u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e34\u003c/span\u003e\u003c/sup\u003e), semaglutide, and aspirin for further evaluation. Aspirin was chosen as it reduced mortality compared to the TB treatment alone arm (although not compared to the control, adjunctive dexamethasone arm), and as it is currently being evaluated in clinical trials for TB meningitis\u003csup\u003e\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e \u003c/div\u003e\n\u003ch3\u003eBactericidal activity and target engagement for the Immunomodulatory drugs\u003c/h3\u003e\n\u003cp\u003eImmunomodulatory drugs could directly affect \u003cem\u003eM. tuberculosis\u003c/em\u003e killing and modulation of host responses could affect (increase or decrease) bacterial killing\u003csup\u003e\u003cspan citationid=\"CR35\" class=\"CitationRef\"\u003e35\u003c/span\u003e\u003c/sup\u003e. To address this, organs (brain, lung and spleen) from a cohort of infected mice were collected two weeks after treatment initiation. The tissues were homogenized and plated to assess bacterial burden as colony forming units (CFU). As expected, TB treatment with isoniazid (antibiotic) alone was associated with a reduction in CFU compared to untreated animals in the brain, lungs, and spleen. However, the addition of none of the 12 immunomodulatory drugs or dexamethasone, significantly altered the organ bacterial burden in the brain, nor increased dissemination to the lungs or spleen (\u003cb\u003eFig. S6\u003c/b\u003e).\u003c/p\u003e \u003cp\u003eSome drugs fail to achieve their effects due to inadequate tissue levels. Drug doses and their brain effects were available for aspirin\u003csup\u003e\u003cspan citationid=\"CR36\" class=\"CitationRef\"\u003e36\u003c/span\u003e\u003c/sup\u003e and montelukast\u003csup\u003e\u003cspan citationid=\"CR37\" class=\"CitationRef\"\u003e37\u003c/span\u003e\u003c/sup\u003e, and were used for the current studies. For other small molecules, Western blots were performed on mouse whole-brain lysates from the treatment cohorts (\u003cb\u003eFig. S6\u003c/b\u003e), demonstrating pathway-appropriate modulation: semaglutide downregulated GLP-1 expression, roflumilast, imatinib, navitoclax and bestatin, respectively decreased PDE-4, PDGFRα/β, BCL2, and CD13, while palacaparib increased PARP-1 cleavage, consistent with its role in inducing apoptosis. Thalidomide and pomalidomide reduced cereblon expression. Collectively, these data confirm that these drugs engage their intended molecular targets within the brain during TB meningitis (\u003cb\u003eFig. S7\u003c/b\u003e).\u003c/p\u003e\n\u003ch3\u003eDynamic contrast-enhanced brain MRI in the mouse model of TB meningitis\u003c/h3\u003e\n\u003cp\u003eNext, we evaluated the effects of the seven promising HDT classes on neuroinflammation using dynamic contrast-enhanced brain MRI in a cohort of \u003cem\u003elive\u003c/em\u003e animals, complemented by post-mortem studies 2-weeks after treatment initiation. Contrast-enhanced imaging can localize areas of local tissue inflammation due to the extravasation of intravenous contrast from inflamed (and leaky) blood vessels\u003csup\u003e\u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e\u003c/sup\u003e. MRI was performed using custom-built MRI compatible biocontainment beds for imaging live animals under biosafety level-3 (BSL-3) containment (\u003cb\u003eFig. S8\u003c/b\u003e). Dynamic contrast enhanced MRI demonstrated contrast enhancement in the periventricular region (site of infection) in infected mice, which persisted throughout the duration of the scan (20 min). No such enhancement was noted in the sham controls (injected with sterile PBS) (\u003cb\u003eFig. S9\u003c/b\u003e). The MRI contrast signal was quantified as the area under the curve (AUC) and normalized to background levels. Delta maps were generated by digitally subtracting the pre-contrast from the post-contrast images (\u003cb\u003eFig. S10\u003c/b\u003e).\u003c/p\u003e \u003cp\u003eInitial studies utilized TB treatment (isoniazid) with or without one of the seven promising HDTs or dexamethasone. TB treatment alone significantly reduced the contrast enhancement compared to untreated animals (\u003cem\u003eP\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.001), which was further reduced in the dexamethasone arm, compared to TB treatment alone (\u003cem\u003eP\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.001) (\u003cb\u003eFig. S11\u003c/b\u003e). Importantly, bestatin, imatinib, roflumilast, palacaparib, pomalidomide, or semaglutide (\u003cem\u003eP\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.040) arms, but not aspirin (\u003cem\u003eP\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.34) or montelukast (signal higher), demonstrated significant reductions in contrast enhancement compared to TB treatment alone (\u003cb\u003eFig.\u0026nbsp;3a, c\u003c/b\u003e). Similar trends were noted in studies utilizing first-line TB treatment (isoniazid\u0026thinsp;+\u0026thinsp;rifampin\u0026thinsp;+\u0026thinsp;pyrazinamide) with or without adjunctive HDTs. As expected, the first-line TB treatment was more efficacious than isoniazid alone in reducing contrast enhancement. All HDTs arms tested (\u003cem\u003eP\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.020), except for aspirin (signal higher) and imatinib (\u003cem\u003eP\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.186), demonstrated further and significant reductions in contrast enhancement compared to the first-line TB treatment alone (\u003cb\u003eFig.\u0026nbsp;3b, c\u003c/b\u003e).\u003c/p\u003e \u003cp\u003e \u003cdiv description=\"The image appears to be a scatter plot or bar chart comparing various treatments for Tuberculosis (TB) and their effectiveness, with different colors and symbols representing different treatment combinations, and statistical significance values (P-values) indicating the significance of the results.AI-generated content may be incorrect.\" class=\"Drawing\" id=\"1821548051\" name=\"Picture 2\"\u003e\u003c/div\u003e \u003cb\u003eFigure\u0026nbsp;3. Dynamic gadolinium-enhanced brain MRI in the mouse model of TB meningitis.\u003c/b\u003e (\u003cb\u003ea\u003c/b\u003e) Representative axial T1-weighted MRI images acquired post-contrast injection (left column) with corresponding delta maps (right column) performed at two weeks after treatment initiation in mice showing contrast enhancement in the periventricular region are shown. TB treatment (isoniazid) or first-line TB treatment (isoniazid\u0026thinsp;+\u0026thinsp;rifampin\u0026thinsp;+\u0026thinsp;pyrazinamide) with or without adjunctive HDT were administered at human equipotent and clinically relevant dosing. (\u003cb\u003eb\u003c/b\u003e) MRI contrast signal was quantified as the area under the curve (AUC) and normalized to background levels. Delta maps were generated by digitally subtracting the pre-contrast image from the post-contrast segmented brain image. Each dot represents a single region of interest (ROI), with 3 brain ROIs drawn for each animal. The dashed line represents the median values for the TB treatment (red line) and the first-line TB treatment (burgundy line) arms. Data are presented as median and interquartile range (IQR). Statistical comparisons were made using the Mann-Whitney U test.\u003c/p\u003e\n\u003ch3\u003eBrain tissue inflammation in the mouse model of TB meningitis\u003c/h3\u003e\n\u003cp\u003eAfter completion of imaging, mice were sacrificed and the brains were collected. Brain tissue inflammation was measured by ionized calcium-binding adaptor molecule 1 (Iba1) immunofluorescence (percentage of area covered by positive staining). As expected, first-line TB treatment (isoniazid\u0026thinsp;+\u0026thinsp;rifampin\u0026thinsp;+\u0026thinsp;pyrazinamide) significantly reduced tissue inflammation compared to untreated animals (\u003cem\u003eP\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.001), which was further reduced in the dexamethasone arm (\u003cem\u003eP\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.001) (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e4\u003c/span\u003e). Importantly, aspirin, bestatin, imatinib, roflumilast, palacaparib, pomalidomide, or semaglutide (\u003cem\u003eP\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.002) arms demonstrated further significant reductions in tissue inflammation, compared to the first-line TB treatment alone arm. Similar trends in brain tissue inflammation were observed in mice receiving TB treatment (isoniazid) with or without HDTs (\u003cb\u003eFig. S12\u003c/b\u003e). We investigated serum glial fibrillary acidic protein (GFAP) in CSF as a clinically relevant biomarker of brain injury\u003csup\u003e\u003cspan citationid=\"CR39\" class=\"CitationRef\"\u003e39\u003c/span\u003e,\u003cspan citationid=\"CR40\" class=\"CitationRef\"\u003e40\u003c/span\u003e\u003c/sup\u003e, which followed the trend noted above (\u003cb\u003eFig. S13\u003c/b\u003e).\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003e \u003cb\u003eEx vivo\u003c/b\u003e \u003cb\u003eimmune-vascularized 3D human brain organoid model of TB meningitis\u003c/b\u003e\u003c/p\u003e \u003cp\u003eTo evaluate the effect of the seven promising HDT classes on human brain resident immune cells, in particular microglia, we employed a strategic investigation using \u003cem\u003eM. tuberculosis\u003c/em\u003e-infected human microglia in an \u003cem\u003eex vivo\u003c/em\u003e immune-vascularized 3D human organoid model. The brain organoid was generated by differentiating human induced pluripotent stem cells (iPSCs) into multipotent forebrain neural stem and neural progenitor cells. In parallel, yolk sac-like tissues from iPSCs were used to generate mesodermal derivatives resembling early extraembryonic hemato-vascular lineages, including CD31\u0026thinsp;+\u0026thinsp;endothelial cells and CD45\u0026thinsp;+\u0026thinsp;hematopoietic progenitors, which further differentiated into microglia and pericyte-like cells. Both the mouse brain and human brain organoid models used in this study exhibit comparable cellular complexity, encompassing key brain-resident cell types relevant to TB meningitis pathophysiology, including microglia, endothelial cells, and pericytes which are critical for modeling infection related neuroinflammatory responses (\u003cb\u003eFig. S14\u003c/b\u003e).\u003c/p\u003e \u003cp\u003ePreliminary viability assays were performed using \u003cem\u003eM. tuberculosis\u003c/em\u003e-infected human microglia to establish the ideal multiplicity of infection (MOI) and time-points after infection (\u003cb\u003eFig. S15\u003c/b\u003e). Co-incubation of each individual HDTs with TB treatment (isoniazid) at the physiologically relevant, expected human brain tissue concentrations achieved with clinically relevant dosing, was performed (\u003cb\u003eTable S2, S3\u003c/b\u003e). TB treatment alone reduced the Iba1 expression compared to untreated controls, which was further reduced with the addition of the promising HDTs tested compared to TB treatment alone in a dose-dependent manner (\u003cb\u003eFig. S16\u003c/b\u003e). Based on these data, we chose the physiologically relevant concentrations (\u003cb\u003eTable S3\u003c/b\u003e). Using mean fluorescence intensity (MFI) of Iba1 all promising HDT classes significantly reduced microglial activation (\u003cem\u003eP\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.030) (\u003cb\u003eFig. S17\u003c/b\u003e). On the contrary, montelukast increased microglial activation, and overall, these results were consistent with the mouse studies.\u003c/p\u003e \u003cp\u003eNext, we performed studies with the brain organoid model where \u003cem\u003eM. tuberculosis\u003c/em\u003e-infected microglia were incorporated into the assembled human brain organoids to generate a complex model comprising immune and non-immune cells and probed with multi-channel immunofluorescence (\u003cb\u003eFig. S18\u003c/b\u003e). \u003cem\u003eM. tuberculosis\u003c/em\u003e-infected, but untreated organoids induced strong microglial activation, marked by increased Iba1, CD11b, and TMEM119 expression (\u003cb\u003eFig. S19\u003c/b\u003e). While the first-line TB treatment (isoniazid\u0026thinsp;+\u0026thinsp;rifampin\u0026thinsp;+\u0026thinsp;pyrazinamide) alone reduced Iba1 levels, the addition of the promising HDTs at physiologically-relevant concentrations (\u003cb\u003eTable S3\u003c/b\u003e) produced a more pronounced suppression of microglial activation (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e5\u003c/span\u003e, S20). Quantitative analysis confirmed significant reductions in Iba1 MFI with each HDTs compared with first-line TB treatment alone (\u003cem\u003eP\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.021) (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e5\u003c/span\u003e). Similar trends were observed in brain organoids receiving TB treatment (isoniazid) with or without HDTs (\u003cb\u003eFig. S21, S22\u003c/b\u003e).\u003c/p\u003e \u003cp\u003e \u003c/p\u003e\n\u003ch3\u003ePeripheral blood mononuclear cells from patients with TB meningitis\u003c/h3\u003e\n\u003cp\u003eFinally, we examined the effects of the seven promising HDT classes on peripheral immune cells, specifically PBMCs, which infiltrate the CNS and play a critical role in the pathogenesis of TB meningitis\u003csup\u003e\u003cspan additionalcitationids=\"CR23\" citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e\u003c/sup\u003e. PBMCs were collected from eight patients with confirmed TB meningitis and two healthy controls. The median age was 39 years (IQR, 33\u0026ndash;41) and 60% (n\u0026thinsp;=\u0026thinsp;6) were female (\u003cb\u003eTable S4\u003c/b\u003e). Half of patients with TB meningitis were PLWH. All of them were on antiretroviral therapy and exhibited Immune Reconstitution Inflammatory Syndrome (IRIS). The other half with TB meningitis exhibited paradoxical reactions. Importantly, samples used in this study were collected during a follow-up visit, and none of the patients were receiving corticosteroids at that timepoint.\u003c/p\u003e \u003cp\u003eThe PBMCs were cultured and re-exposed to live \u003cem\u003eM. tuberculosis\u003c/em\u003e to induce the expression of a specific mycobacterial immune response (\u003cb\u003eFig. S23\u003c/b\u003e). After washing off the bacteria, the cells were treated with first-line TB treatment (isoniazid\u0026thinsp;+\u0026thinsp;rifampin\u0026thinsp;+\u0026thinsp;pyrazinamide), with or without HDTs at physiological and clinically relevant doses (\u003cb\u003eTable S3\u003c/b\u003e) and analyzed using multiparametric flowcytometry (\u003cb\u003eFig. S24\u003c/b\u003e). Most of the cells recovered were CD4\u0026thinsp;+\u0026thinsp;T-cells (median 32.7%, IQR 32.2\u0026ndash;33.5%) and CD8\u0026thinsp;+\u0026thinsp;T-cells (median 27.9%, IQR 26.6\u0026ndash;29.5%), with no significant differences in the proportion of cells induced by HDT treatments (\u003cb\u003eFig. S25\u003c/b\u003e).\u003c/p\u003e \u003cp\u003eFlow cytometry analyses showed the induction of proinflammatory cytokines, specifically a strong IFNγ expression on CD4\u0026thinsp;+\u0026thinsp;T-cells upon re-exposure to live \u003cem\u003eM. tuberculosis\u003c/em\u003e on PBMCs from patients with TB meningitis \u003cb\u003e(\u003c/b\u003eFig.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e6\u003c/span\u003ea\u003cb\u003e)\u003c/b\u003e. Adjunctive HDTs decreased both the expression and the proportion of IFNγ positive CD4\u0026thinsp;+\u0026thinsp;T-cells, evaluated by the IFNγ integrated MFI (iMFI) (Fig.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e6\u003c/span\u003eb-d). Other proinflammatory cytokines, including IL-1β and TNFα, followed a similar trend, with decreased expression in response to adjunctive HDTs. In contrast, IL-2 and IL-10 showed minimal changes (\u003cb\u003eFig. S26, S27\u003c/b\u003e).\u003c/p\u003e \u003cp\u003eA similar approach was applied using PBMCs isolated from the mouse model of TB meningitis (n\u0026thinsp;=\u0026thinsp;40 animals) (\u003cb\u003eFig. S28-S30\u003c/b\u003e). Consistent with the results from human PBMCs and aligned with the brain organoid studies, adjunctive HDTs were associated with downregulation of the proinflammatory response, such as IFNγ in CD4\u0026thinsp;+\u0026thinsp;T-cells (\u003cb\u003eFig. S31\u003c/b\u003e), as well as other cytokines such as IL-1β, TNFα, and IL-4 (\u003cb\u003eFig. S32, S33\u003c/b\u003e).\u003c/p\u003e \u003cp\u003e \u003c/p\u003e"},{"header":"DISCUSSION","content":"\u003cp\u003eThe treatment of TB meningitis remains challenging due to the inconsistent and suboptimal penetration of many TB antibiotics into the brain\u003csup\u003e\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e,\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e\u003c/sup\u003e, and current efforts to optimize antibiotic regimens have thus far only demonstrated partial success in clinical trials. For example, while higher doses of rifampin are being evaluated to overcome its limited CNS penetration; clinical trial data regarding efficacy remain conflicting\u003csup\u003e\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e,\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e,\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e,\u003cspan citationid=\"CR41\" class=\"CitationRef\"\u003e41\u003c/span\u003e,\u003cspan citationid=\"CR42\" class=\"CitationRef\"\u003e42\u003c/span\u003e\u003c/sup\u003e. While increasing rifampin dosing was shown to improve mortality or neurological outcomes in phase II clinical trials in adults and children respectively\u003csup\u003e\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e,\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e\u003c/sup\u003e, these benefits were not translated into improved clinical outcomes (mortality or neurological deficits) in a recent larger clinical trial\u003csup\u003e\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e\u003c/sup\u003e. Although the exact reason(s) for this lack of benefit from high-dose rifampin remain unknown, reduced corticosteroids exposure resulting from rifampin-induced hepatic clearance, has been postulated as a leading factor. Similarly, clinical studies have shown that the LTA4H genotype (leukotriene pathway) modulates intracerebral inflammation with maximal benefit of corticosteroids noted in TB meningitis patients with the hyperinflammatory TT genotype\u003csup\u003e\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e,\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e\u003c/sup\u003e. However, these benefits were again not translated into improved clinical outcomes (mortality or neurological deficits) in genotype-stratified TB meningitis patients expected to benefit differentially from adjunctive corticosteroids in a recent, larger clinical trial\u003csup\u003e\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e\u003c/sup\u003e. Together, these findings underscore a critical unmet therapeutic need for developing new HDTs that can more selectively modulate neuroinflammation without broadly suppressing protective immune responses. With this understanding, HDTs have emerged as an essential rather than optional strategy to develop new treatments for TB meningitis. Accordingly, we investigated a panel of 12 immunomodulatory drugs, representing 11 different immunomodulatory drug classes, which are either FDA-approved or in advanced clinical development for other indications, as potential adjunctive treatments to replace corticosteroids for the management of TB meningitis.\u003c/p\u003e \u003cp\u003eExtensive studies using clinical endpoints, with longitudinal monitoring, were performed in a mouse model of TB meningitis. The mouse studies were complemented by parallel mechanistic studies to evaluate the effects of these HDTs (at expected human tissue concentrations) on both human brain resident and peripheral immune cells, in a newly developed 3D immune-vascularized brain organoid model of TB meningitis and PBMCs from patients with TB meningitis, respectively. The murine model enabled the evaluation of mortality, neurological deficits and MRI-based brain imaging that mirror key clinical trial endpoints, while also correlating these findings with post-mortem immunopathology assays, which are not feasible in humans. Human equipotent drug dosing was utilized to ensure that these findings were relevant to the clinically approved (or proposed) dosing for these immunomodulatory drugs. Human organoids comprising endogenous human neural, vascular, and immune cells, enabled direct assessment of inflammatory responses within the human brain. Because the pathogenesis of active TB meningitis involves both CNS-resident and peripheral immune mechanisms\u003csup\u003e\u003cspan additionalcitationids=\"CR23\" citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e\u003c/sup\u003e, the complementary use of brain organoids and PBMCs allowed us to capture these interacting compartments and demonstrate human-relevant immunomodulatory effects. Notably, these complex 3D systems provide a human-based system to interrogate immune-vascular mechanisms underlying neuroinflammation\u003csup\u003e\u003cspan citationid=\"CR43\" class=\"CitationRef\"\u003e43\u003c/span\u003e,\u003cspan citationid=\"CR44\" class=\"CitationRef\"\u003e44\u003c/span\u003e\u003c/sup\u003e, as a non-animal-based Novel Alternative Methods or New Approach Methodologies (NAMs) with extensive human-relevant applications\u003csup\u003e\u003cspan citationid=\"CR45\" class=\"CitationRef\"\u003e45\u003c/span\u003e\u003c/sup\u003e. This cross-species multi-model analysis strengthens the translational relevance of our findings by bridging mechanistic insight with clinical applicability.\u003c/p\u003e \u003cp\u003eTo rationally prioritize candidates, we performed initial studies in an established mouse model that recapitulates the histopathological and imaging features of TB meningitis\u003csup\u003e\u003cspan additionalcitationids=\"CR26\" citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e\u003c/sup\u003e. We evaluated each HDT as an adjunct to isoniazid alone, using relevant drug dosing informed by existing \u003cem\u003ein vitro\u003c/em\u003e, preclinical, and clinical pharmacokinetic data, including evidence of brain penetration. This approach enabled meaningful rank-ordering of HDTs based on clinically-comparable outcomes, which would not be feasible with studies using the first-line TB treatment (isoniazid\u0026thinsp;+\u0026thinsp;rifampin\u0026thinsp;+\u0026thinsp;pyrazinamide), which is highly efficacious and would require an unmanageable large sample size to detect any additional therapeutic benefit\u003csup\u003e\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e,\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e\u003c/sup\u003e. Our approach also focused on modulating host responses during the initial phase (2-weeks) of TB treatments, as this period is associated with high mortality in patients with TB meningitis, and thus an ideal time for intervention\u003csup\u003e\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e,\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e,\u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e,\u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e\u003c/sup\u003e. The investigators were blinded to the treatment assignments for these studies. Notably, we identified several HDTs including bestatin (protease inhibitor), imatinib (tyrosine kinase inhibitor), roflumilast (PDE-4 inhibitor), or palacaparib (PARP-1 inhibitor) that reduced both mortality and neurological deficits, when compared with dexamethasone. In addition, a broader set of HDTs, thalidomide / pomalidomide (IMiDs), and semaglutide (GLP-1 receptor agonist) markedly reduced severe neurological deficits compared with our control (isoniazid); importantly, these neurological benefits were not observed with adjunctive dexamethasone, consistent with clinical data and highlighting therapeutic effects beyond the current standard of care\u003csup\u003e\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e,\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e\u003c/sup\u003e. Further validation of the therapeutic efficacy was performed in animals receiving adjunctive HDTs with the first-line TB treatment. Several HDTs preserved the immunomodulatory benefits observed when used in combination with isoniazid alone, indicating that their effects are not masked by potent antimicrobial treatment. Palacaparib, bestatin, roflumilast, and pomalidomide consistently reduced brain MRI contrast enhancement and microglial activation compared with the first-line TB treatment alone, while semaglutide and imatinib showed more modest effects. The modest additive effects of imatinib when used with the first-line TB treatment versus isoniazid alone could be explained due to the increased metabolism of imatinib when co-administered with rifampin\u003csup\u003e\u003cspan citationid=\"CR46\" class=\"CitationRef\"\u003e46\u003c/span\u003e\u003c/sup\u003e. Adjunctive use of other tyrosine kinase\u003csup\u003e\u003cspan citationid=\"CR47\" class=\"CitationRef\"\u003e47\u003c/span\u003e\u003c/sup\u003e and PDE-4 inhibitors\u003csup\u003e\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e\u003c/sup\u003e have shown to reduce pulmonary inflammation in animal models of TB, and improve lung function in patients with pulmonary TB\u003csup\u003e48\u003c/sup\u003e. Interestingly, pyrazinamide, an important TB drug, may also influence its effects through PARP-1 inhibition\u003csup\u003e\u003cspan citationid=\"CR49\" class=\"CitationRef\"\u003e49\u003c/span\u003e\u003c/sup\u003e. However, addition of palacaparib (PARP-1 inhibitor) to the first-line TB treatment (which includes pyrazinamide), substantially and further reduced neuroinflammation in our mouse, human brain organoid and human PBMC studies. Although, initial studies with thalidomide at a high-dose (24 mg/kg/day) demonstrated worse outcomes in children\u003csup\u003e\u003cspan citationid=\"CR50\" class=\"CitationRef\"\u003e50\u003c/span\u003e\u003c/sup\u003e, recent observational studies have shown that thalidomide at a dose of 3\u0026ndash;5 mg/kg/day is safe and improves outcomes in children with CNS TB-related complications\u003csup\u003e\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e\u003c/sup\u003e. Thalidomide is readily available and in our mouse studies, adjunctive thalidomide at a human equipotent dosing of 3\u0026ndash;5 mg/kg/day, was most effective in reducing neurological deficits, with mortality rates similar to dexamethasone. While adjunctive high-dose aspirin (500\u0026ndash;1000 mg) is being used to target inflammation in TB meningitis clinical trials\u003csup\u003e\u003cspan citationid=\"CR51\" class=\"CitationRef\"\u003e51\u003c/span\u003e\u003c/sup\u003e, and we modeled using high-dose aspirin in our studies reported here, clinical evidence has been mixed, with no consistent benefit demonstrated in either children (SURE trial) or adults\u003csup\u003e\u003cspan citationid=\"CR52\" class=\"CitationRef\"\u003e52\u003c/span\u003e,\u003cspan citationid=\"CR53\" class=\"CitationRef\"\u003e53\u003c/span\u003e\u003c/sup\u003e. Similarly, although retrospective cohort studies and case series have demonstrated benefit of infliximab and montelukast as rescue therapies for paradoxical reactions or IRIS\u003csup\u003e\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e,\u003cspan citationid=\"CR54\" class=\"CitationRef\"\u003e54\u003c/span\u003e,\u003cspan citationid=\"CR55\" class=\"CitationRef\"\u003e55\u003c/span\u003e\u003c/sup\u003e, our findings show that infliximab did not reduce mortality nor improve neurological outcomes, while montelukast was the poorest-performing HDT and in some measures worsened neuroinflammatory outcomes. These findings highlight the selective pathways that may be critical for therapeutic benefit in TB meningitis, and that upfront HDT treatments may be different from treatments in later inflammatory reactions, which may not fully reflect early CNS-resident immune responses.\u003c/p\u003e \u003cp\u003eBuilding on this approach, we employed human microglial cultures to test these HDTs at physiological concentrations which revealed that, except montelukast, all the tested HDTs reduced microglial activation compared with isoniazid alone, enabling selection of the most physiologically relevant dose for downstream studies. Similarly, when tested at chosen clinically achievable concentrations, all the HDTs, except montelukast, significantly suppressed Iba1 expression in \u003cem\u003eM. tuberculosis\u003c/em\u003e-infected human microglia. Extending these observations to a more human-relevant context, we next incorporated these \u003cem\u003eM. tuberculosis\u003c/em\u003e-infected human microglia into the human brain organoid model, enabling evaluation of HDT effects within a multicellular neural environment in combination with either isoniazid alone or first-line TB treatment. Across both treatment settings, most HDTs significantly reduced microglial activation within infected organoids, as reflected by decreased Iba1 signal, whereas montelukast again failed to confer considerable benefit. Notably, the preserved efficacy of these HDTs in organoids treated with the first-line TB treatment demonstrates that their immunomodulatory effects are not masked by potent antimicrobial activity or within complex, human brain-like tissue architectures.\u003c/p\u003e \u003cp\u003eFinally, we used PBMCs derived from both patients with TB meningitis and the mouse model of TB meningitis to demonstrate the anti-inflammatory effects of these HDTs on the immune response to \u003cem\u003eM. tuberculosis\u003c/em\u003e. Because corticosteroids are recommended and administered early to patients with confirmed TB meningitis, we used samples from patients in cohorts with paradoxical reactions and IRIS, obtained at a follow-up timepoint after corticosteroids were discontinued. Of note, all PLWH in this cohort were on anti-retroviral treatments for several weeks at this follow-up timepoint. These cells were re-stimulated with live \u003cem\u003eM. tuberculosis\u003c/em\u003e and exhibited a strong IFNγ response. This system demonstrated that adjunctive HDTs at physiological doses modulated the inflammatory response in peripheral immune cells, which play a critical role both in the peripheral compartment and once they infiltrate the CNS\u003csup\u003e\u003cspan additionalcitationids=\"CR23\" citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e\u003c/sup\u003e. Importantly, these findings were consistent, though not identical, between human and mouse cells, demonstrating a conserved anti-inflammatory effect despite the heterogeneities across species and highlighting the clinical relevance of these findings.\u003c/p\u003e \u003cp\u003eOur study has some limitations. Pharmacokinetic and metabolic differences between mice and humans - particularly for drugs affected by rifampin-mediated cytochrome P450 induction that may require dosing optimization or rifampin-sparing regimens\u003csup\u003e\u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e,\u003cspan citationid=\"CR46\" class=\"CitationRef\"\u003e46\u003c/span\u003e,\u003cspan additionalcitationids=\"CR57\" citationid=\"CR56\" class=\"CitationRef\"\u003e56\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR58\" class=\"CitationRef\"\u003e58\u003c/span\u003e\u003c/sup\u003e. In addition, human immune-vascularized brain organoids do not capture full patient-level genetic heterogeneity, and PBMCs obtained at follow-up from a cohort exhibiting paradoxical reactions and/or IRIS may not fully reflect early CNS-resident immune responses. However, our human brain organoid studies did capture the early CNS-resident immune responses, and the effects of the HDTs were consistent with the results noted from patient- as well as mouse-derived PBMCs. Of note, mouse-derived PBMCs also reflected early immune responses. Also, the small sample size further limits the ability to perform multivariable analysis, underscoring the importance of integrating these data with animal models. Future studies expanding patient-derived brain organoids and PBMC analyses to capture genetic, immunological, and disease-stage heterogeneity, particularly during acute disease, would further improve the translational relevance and guide precision clinical trials.\u003c/p\u003e \u003cp\u003eIn conclusion, this study is one of the most comprehensive evaluations of promising HDTs across complementary experimental systems - including mouse models with clinically-relevant endpoints (mortality, neurological deficit, brain MRI), human immune-vascularized brain organoids, and patient-derived PBMCs. These approaches demonstrate that several targeted immunomodulatory drug classes outperform dexamethasone in reducing neuroinflammation, mortality risk, and neurological injury in TB meningitis. By enabling mechanism-specific modulation of pathogenic inflammation without compromising antimicrobial efficacy, these findings provide a strong translational rationale for advancing select immunomodulatory drug classes into early-intervention clinical trials to improve survival and long-term neurological outcomes.\u003c/p\u003e"},{"header":"METHODS","content":"\u003cdiv id=\"Sec10\" class=\"Section2\"\u003e \u003ch2\u003eAnimal studies\u003c/h2\u003e \u003cp\u003eAll protocols were approved by the Johns Hopkins University Biosafety, Radiation Safety, Animal Care and Use Committees (MO19M382).\u003c/p\u003e \u003cp\u003eFemale C3HeB/FeJ mice (6\u0026ndash;8 weeks old, Jackson Laboratory) were infected (titrated frozen stocks with ~\u0026thinsp;6.5 log\u003csub\u003e10\u003c/sub\u003e CFU of \u003cem\u003eM. tuberculosis\u003c/em\u003e H37Rv) via a burr hole (Micro-Drill Kit, Braintree Scientific Inc.) using a Hamilton syringe (Hamilton, 255 88000) and stereotaxic instrument (David KOPF Instruments, model 900, coordinates 0.6 mm dorsal to bregma, 1.2 mm lateral to middle line, and 2 mm ventral). Sham mice that received intracranial injections of sterile PBS, rather than bacteria, served as controls to distinguish the effects of the infection from those due to the intracranial injection procedure itself. All animals were housed in controlled light and temperature rooms without cross-ventilation in a BSL-3 facility with unrestricted access to both food and water.\u003c/p\u003e \u003cp\u003e \u003cem\u003eTreatments\u003c/em\u003e: All drugs were purchased from MedChem and were either dissolved or suspended in water per the manufacturer instructions. All drugs and antibiotics were prepared and administered daily, five days per week, except for semaglutide and infliximab, which were administered every other day and once weekly, respectively, at the indicated dose and route. The immunomodulatory drug doses were chosen to simulate clinically relevant doses for immunomodulatory effects in humans, while accounting for mouse pharmacokinetics (\u003cb\u003eTable \u003cspan refid=\"MOESM1\" class=\"InternalRef\"\u003eS1\u003c/span\u003e, S2\u003c/b\u003e). The 5-day-on / 2-day-off schedule is standard for treatments in the mouse models of TB to approximate continuous daily therapy while accounting for animal handling and welfare. In addition, clinical guidelines and extensive programmatic experience interpret directly observed therapy given 5 days per week as equivalent to 7-day \u0026ldquo;daily\u0026rdquo; therapy, with comparable treatment success when the total number of doses is adjusted accordingly. TB antibiotics were administered at the following doses: isoniazid (10 mg/kg/day), rifampin (10 mg/kg/day), and pyrazinamide (150 mg/kg/day). Bacterial burden was quantified in whole organs (brain, lung and spleen) as CFU following two weeks of treatments using 7H11 plates supplemented with activated charcoal. Plates were incubated at 37\u0026deg;C for three weeks before CFU were counted.\u003c/p\u003e \u003cp\u003e \u003cstrong\u003eSurvival and neurological signs assessment\u003c/strong\u003e \u003cp\u003eCohorts of animals were individually marked for identification and randomly assigned to each treatment group. Mice were evaluated each week for survival, weight changes and development of neurological signs. Evident head tilt and partial or complete unilateral or bilateral limb paralysis were considered as development of severe neurological signs. The investigators were blinded to the treatment assignments for the survival and neurological deficit studies.\u003c/p\u003e \u003c/p\u003e \u003cp\u003e \u003cstrong\u003eDynamic gadolinium-enhanced brain MRI\u003c/strong\u003e \u003cp\u003eMultislice Fast Spin Echo T1-weighted (T1w-FSE; repetition time (TR)\u0026thinsp;=\u0026thinsp;1000 ms; echo time (TE)\u0026thinsp;=\u0026thinsp;11 ms; number of averages\u0026thinsp;=\u0026thinsp;1; field of view (FOV)\u0026thinsp;=\u0026thinsp;2 \u0026times; 2 cm; matrix size\u0026thinsp;=\u0026thinsp;256 \u0026times; 248; slice thickness\u0026thinsp;=\u0026thinsp;1 mm; number of slices\u0026thinsp;=\u0026thinsp;14\u0026ndash;16; fat saturation applied) and FLASH Dynamic Contrast-Enhanced Magnetic Resonance Imaging (FLASH DCE-MRI; TR\u0026thinsp;=\u0026thinsp;100 ms; TE\u0026thinsp;=\u0026thinsp;4 ms; flip angle\u0026thinsp;=\u0026thinsp;25\u0026deg;; number of averages\u0026thinsp;=\u0026thinsp;1; FOV\u0026thinsp;=\u0026thinsp;2 \u0026times; 2 cm; matrix size\u0026thinsp;=\u0026thinsp;192 \u0026times; 100; slice thickness\u0026thinsp;=\u0026thinsp;1 mm; number of slices\u0026thinsp;=\u0026thinsp;11; time of scan\u0026thinsp;=\u0026thinsp;5 or 20 minutes, intervals of 10 seconds) were performed before and after intravenous injection of gadolinium-based contrast (Magnevist, Bayer; 0.2 mmol/kg) to assess brain changes in response to treatment. Imaging was performed using a 7T MRI system (MRS DRYMAG, MRSolutions, UK) equipped with a Quadrature 20 mm-diameter mouse head coil and custom-built animal biosafety level-3 (ABSL-3) MRI-compatible biocontainers (\u003cb\u003eFig. S8\u003c/b\u003e). VivoQuant, Preclinical ScanTM and PowerscanTM were used for MRI data analysis. AUC were calculated for the segmented whole-brain region from dynamic MR images by summing the difference maps (post-/pre-contrast) across all experimental timepoints during the 5\u0026ndash;20 min acquisition and normalizing by background. Delta maps were generated by digitally subtracting the pre-contrast image from the post-contrast image after manual segmentation of the whole brain.\u003c/p\u003e \u003c/p\u003e \u003cp\u003e \u003cem\u003eHistopathology and immunofluorescence\u003c/em\u003e: Mice were sacrificed two weeks after treatment initiation and organs (brain, lung and spleen) were harvested and fixed after systemic perfusion with 4% paraformaldehyde. Multiple random slides were obtained from each tissue sample, stained and digitally scanned. Slides were incubated overnight at 4\u0026deg;C with a primary antibody against Iba1 (Thermo Fisher MA5-36257, 1:500). After washing the sections, a secondary goat Alexa-fluor 488 antibody (Thermo Fisher, A11034, 1:100) was used to incubate the tissues for 2 h at room temperature. Sections were washed and mounted with 4',6-diamidino-2-phenylindole (DAPI, Thermo Fisher, ProLong\u0026trade; Gold Antifade Mountant with DNA Stain DAPI). Leica DM6B system (Leica) confocal microscope was used at 40x resolution to image. For data analysis, ten to 15 images per sample were processed in FIJI ImageJ to determine the % area staining for Iba1.\u003c/p\u003e \u003cp\u003e \u003cstrong\u003eCSF and brain homogenate assays\u003c/strong\u003e \u003cp\u003eAnimals were sacrificed and CSF, and brain tissue were extracted. Western blot analysis was performed on brain lysate using a standardized protocol using specific primary and secondary antibodies (\u003cb\u003eTable S5\u003c/b\u003e). The protein bands were visualized on the membranes using chemiluminescent substrates (Supersignal West Pico maximum sensitivity substrate, cat. no. 34580) and analyzed using FIJI ImageJ (NIH).\u003c/p\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec11\" class=\"Section2\"\u003e \u003ch2\u003eHuman microglia\u003c/h2\u003e \u003cp\u003ePreliminary studies were performed to determine the optimum MOI and timepoint for downstream assays (\u003cb\u003eFig. S15\u003c/b\u003e). Cell viability was assessed using lactate dehydrogenase release assay (CyQUANT LDH Cytotoxicity Assays, cat. no. C20301). Based on the results, MOI 5 at 24 hours was selected for all subsequent studies.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec12\" class=\"Section2\"\u003e \u003ch2\u003eHuman brain organoid model of TB meningitis\u003c/h2\u003e \u003cp\u003eHuman iPSCs were maintained in DMEM/F12 supplemented with KnockOut Serum Replacement, FGF2, GlutaMAX, non-essential amino acids, and 2-mercaptoethanol under Johns Hopkins ISCRO approval. Neural differentiation was initiated by collagenase-mediated detachment and suspension culture, followed by dual-SMAD inhibition (Noggin, dorsomorphin, SB431542). Embryoid bodies were plated on Matrigel or laminin to generate neural rosettes, from which rosette-derived neural aggregates (RONAs) were isolated and maintained as neurospheres in Neurobasal medium. Neural rosettes were expanded into glial progenitor cells and differentiated into astrocytes using defined induction and maturation media, including CNTF, over a 4-week period. Human iPSCs were differentiated into yolk sac-like tissues using staged cytokine-driven protocols to generate macrophage-like microglial progenitors, along with endothelial and pericyte populations. Floating microglial progenitors were collected after 25 days and maintained in microglia growth medium for downstream studies\u003csup\u003e\u003cspan citationid=\"CR59\" class=\"CitationRef\"\u003e59\u003c/span\u003e\u003c/sup\u003e. \u003cem\u003eM. tuberculosis\u003c/em\u003e-infected microglia were incorporated into the organoids containing endothelial cells and pericytes. Whole organoids were treated at the specific drug concentrations for 24 hours and then formalin fixed and stained for multiple markers (\u003cb\u003eTable S5\u003c/b\u003e).\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec13\" class=\"Section2\"\u003e \u003ch2\u003ePBMCs obtained from patients with TB meningitis\u003c/h2\u003e \u003cp\u003eHuman studies were approved by the NIH Institutional Review Board, and studies with de-identified samples were performed. PBMCs were collected from eight patients with confirmed TB meningitis and two healthy controls from prospective observational studies (NCT00286767, NCT02147405, NCT04052022) at the National Institutes of Health (NIH). All participants provided written informed consent. The samples were collected during a follow-up visit, and none of the patients were receiving corticosteroids at that time (\u003cb\u003eTable S4\u003c/b\u003e). One day prior to infection, PBMCs were thawed, washed and cultured in complete RPMI (cRPMI) supplemented with 10% FBS, 1 mM sodium pyruvate, and 1% non-essential amino acids at 37\u0026deg;C in 5% CO\u003csub\u003e2\u003c/sub\u003e (\u003cb\u003eFig. S23\u003c/b\u003e). \u003cem\u003eM. tuberculosis\u003c/em\u003e was cultured for two weeks in Middlebrook 7H9 medium. Cells suspended in the supernatant were separated and adherent cells (mainly monocytes) were infected for 4 hours at a multiplicity of infection (MOI) of 1:5 based on 10% monocyte number. After infection, bacteria were washed off, and the cells in the supernatant were returned to the culture and resuspended in cRPMI supplemented with the drugs at the indicated concentrations (\u003cb\u003eTable S3\u003c/b\u003e). After 20 hours of treatment, cells were stimulated with Cell Stimulation Cocktail (e.g., PMA/Ionomycin) together with GolgiStop/GolgiPlug (BD Biosciences) for 4 hours to block cytokine secretion.\u003c/p\u003e \u003cp\u003e \u003cem\u003eMouse PBMCs\u003c/em\u003e: Peripheral blood was collected from mice two weeks after TB meningitis infection. PBMCs were isolated using HISTOPAQUE\u0026reg;-1077 and stored at -80\u0026deg;C. One day prior to infection, PBMCs were thawed and cultured in cRPMI at 37\u0026deg;C in 5% CO₂ (\u003cb\u003eFig. S28\u003c/b\u003e). PBMCs were infected for 4 hours at a multiplicity of infection (MOI) of 1:5 based on 10% monocyte number. After infection, cells were washed and resuspended in cRPMI with drugs at the indicated concentrations (\u003cb\u003eTable S3\u003c/b\u003e). After 24 hours of treatment, supernatants were collected for cytokine quantification. Cells were then resuspended in medium and stimulated with Cell Stimulation Cocktail (e.g., PMA/Ionomycin) together with GolgiStop/GolgiPlug (BD Biosciences) for 4 hours to block cytokine secretion.\u003c/p\u003e \u003cp\u003e \u003cstrong\u003eFlow Cytometry\u003c/strong\u003e \u003cp\u003eAntibodies used for human and mouse staining are listed in \u003cb\u003eTable S6\u003c/b\u003e. Cells were washed in PBS and stained for viability using Fixable Viability Dye Live/Dead Blue (Invitrogen, L23105). After washing with FACS buffer (PBS\u0026thinsp;+\u0026thinsp;0.5% BSA), Fc blocking was performed for 10 minutes at room temperature using Human Fc Block (BD Biosciences, 564220) or Mouse Fc Block (BD Biosciences, 553142). Surface staining was performed in 100 \u0026micro;L of FACS buffer using a surface antibody cocktail for 20 minutes at 4\u0026deg;C. Cells were then fixed and permeabilized using the Fixation/Permeabilization Solution Kit (eBioscience, 00-5521-00). Following fixation, cells were washed with Permeabilization/Wash buffer (eBioscience, 00-8333-56) and Cytofix/Cytoperm (BD Biosciences, 554714); intracellular staining was performed in 100 \u0026micro;L of the same buffer with an intracellular antibody cocktail for 1 hour at 4\u0026deg;C. After staining, cells were resuspended in FACS buffer and acquired on a 5-laser Cytek Aurora spectral flow cytometer (Bayview Immunomics Core, Johns Hopkins Bayview Campus, MD). Data were analyzed using FlowJo v11 (BD) with gating strategies shown (\u003cb\u003eFig. S24, S29\u003c/b\u003e). High-dimensional analysis of cell phenotypes was performed using the FlowJo plugins DownSample v3 and UMAP. Integrated mean fluorescence intensity (iMFI) was calculated by multiplying the mean fluorescence intensity of each marker by the percentage of positive cells.\u003c/p\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec14\" class=\"Section2\"\u003e \u003ch2\u003eStatistical analysis\u003c/h2\u003e \u003cp\u003eData was analyzed using Prism 10 Version 10.1.1 (GraphPad). Bacterial burden (CFUs) are represented on a logarithmic scale (base 10) as mean\u0026thinsp;\u0026plusmn;\u0026thinsp;SD and all other data are represented as median\u0026thinsp;\u0026plusmn;\u0026thinsp;IQR. Comparisons were made using a single-tailed Wilcoxon, Mann-Whitney U or Chi-square test to the predefined control group. RR and 95% CI were calculated using the Katz log rank test. \u003cem\u003eP\u003c/em\u003e values\u0026thinsp;\u0026le;\u0026thinsp;0.05 were considered statistically significant. No sex-based analyses were performed because the study design was not explicitly set up to examine sex differences.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec15\" class=\"Section2\"\u003e \u003ch2\u003eDATA AVAILABILITY\u003c/h2\u003e \u003cp\u003eAll data are available in the main text or the supplementary materials. Source data are provided with this paper.\u003c/p\u003e \u003c/div\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eAcknowledgments\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eWe thank all the participants in the clinical studies. This work was funded by the U.S. National Institutes of Health R01-AI145435-A1, R01-AI153349, R56-AI179012-A1, R01-AI190038, and S10-OD030381-A1 to S.K.J. This research was also supported in part by the\u0026nbsp;Intramural Research Program of the National Institutes of Health (D.T., M.T.S., N.H.G., M.M. and I.S.), Johns Hopkins Alzheimer\u0026apos;s Disease Research Center (JHADRC) Faculty Award P30-AG066507 (K.L. and J-C.X.) and R01-AI152688 (Y.M-M. and W.R.B.). The\u0026nbsp;contributions of the NIH authors are considered Works of the United States Government. The findings and conclusions presented in this paper are those of the author(s) and do not necessarily reflect the views of the NIH or the U.S. Department of Health and Human Services.\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003cstrong\u003eAuthor contributions\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eC.E.R-G., M.S. and S.K.J. conceptualized and designed the studies. C.E.R-G., M.S., Y.M-L. and Y.M-M. performed the \u003cem\u003ein vitro\u003c/em\u003e studies. W.R.B. provided material support and advise for the PBMC studies. C.E.R-G., Y.M-L. and X.C. performed animal studies with help from M.S. M.O.S., S.P. and ML.S. K.L. and J-C.X. developed and provided brain organoids. D.T., M.T.S. and N.H.G. formulated and provided the IMiDs. They were also involved with the study design and analyses of these study data. C.E.R-G. and D.A. developed the imaging protocols and analyzed the MRI data. C.E.R-G., A.V-R. and F.D. designed the flow cytometry protocols and analyzed the data. R.H. provided advice on the selection of immunomodulatory drugs. M.M. and I.S. designed and developed the human cohorts and recruited / consented the human participants. They were also involved with the study design and analyses of these study data. C.E.R-G. and M.S., with support from Y.M-L., and A.V-R., analyzed all the study data. S.K.J. provided funding and supervised the project. C.E.R-G., M.S., Y.M-L. and S.K.J. wrote the manuscript with substantial input from all co-authors.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003cstrong\u003eCompeting interests\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAll authors declare that they have no competing interests.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003eGlobal tuberculosis report 2025 (2025) World Health Organization\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDodd PJ et al (2021) The global burden of tuberculous meningitis in adults: A modelling study. PLOS Glob Public Health 1:e0000069\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eStadelman AM et al (2020) Treatment Outcomes in Adult Tuberculous Meningitis: A Systematic Review and Meta-analysis. Open Forum Infect Dis 7:ofaa257\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWen L et al (2019) Clinical features, outcomes and prognostic factors of tuberculous meningitis in adults worldwide: systematic review and meta-analysis. J Neurol 266:3009\u0026ndash;3021\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWang MG et al (2019) Treatment outcomes of tuberculous meningitis in adults: a systematic review and meta-analysis. BMC Pulm Med 19:200\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWilkinson RJ et al (2017) Tuberculous meningitis. Nat Rev Neurol 13:581\u0026ndash;598\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eJain SK et al (2018) Tuberculous meningitis: a roadmap for advancing basic and translational research. Nat Immunol 19:521\u0026ndash;525\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDonovan J et al (2025) A clinical practice guideline for tuberculous meningitis. Lancet Infect Dis\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eShane SJ, Clowater RA, Riley C (1952) The treatment of tuberculous meningitis with cortisone and streptomycin. Can Med Assoc J 67:13\u0026ndash;15\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePrasad K, Singh MB, Ryan H (2016) Corticosteroids for managing tuberculous meningitis. Cochrane Database Syst Rev 4:CD002244\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDonovan J et al (2023) Adjunctive Dexamethasone for Tuberculous Meningitis in HIV-Positive Adults. N Engl J Med 389:1357\u0026ndash;1367\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRuslami R et al (2013) Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. Lancet Infect Dis 13:27\u0026ndash;35\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eParadkar MS et al (2022) Randomized Clinical Trial of High-Dose Rifampicin With or Without Levofloxacin Versus Standard of Care for Pediatric Tuberculous Meningitis: The TBM-KIDS Trial. Clin Infect Dis 75:1594\u0026ndash;1601\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eTobin DM et al (2012) Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections. Cell 148:434\u0026ndash;446\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eThuong NTT et al (2017) Leukotriene A4 Hydrolase Genotype and HIV Infection Influence Intracerebral Inflammation and Survival From Tuberculous Meningitis. J Infect Dis 215:1020\u0026ndash;1028\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMeya DB et al (2025) Trial of High-Dose Oral Rifampin in Adults with Tuberculous Meningitis. N Engl J Med 393:2434\u0026ndash;2446\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDonovan J et al (2026) Genotype-stratified adjunctive dexamethasone for tuberculous meningitis in HIV-negative adults: a randomized controlled phase 3 trial. Nat Med\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBhatia R et al (2025) A randomised trial to assess the efficacy of add on therapy with aspirin or clopidogrel to the standard medical therapy alone in patients with tubercular meningitis: ACT TBM. Lancet Reg Health Southeast Asia 37:100604\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eManesh A et al (2023) Effectiveness of Adjunctive High-Dose Infliximab Therapy to Improve Disability-Free Survival Among Patients With Severe Central Nervous System Tuberculosis: A Matched Retrospective Cohort Study. Clin Infect Dis 77:1460\u0026ndash;1467\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003evan Toorn R, Solomons RS, Seddon JA, Schoeman JF (2021) Thalidomide Use for Complicated Central Nervous System Tuberculosis in Children: Insights From an Observational Cohort. Clin Infect Dis 72:e136\u0026ndash;e145\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003evan Toorn R et al (2021) The use of thalidomide to treat children with tuberculosis meningitis: A review. Tuberculosis (Edinb) 130:102125\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBe NA, Kim KS, Bishai WR, Jain SK (2009) Pathogenesis of central nervous system tuberculosis. Curr Mol Med 9:94\u0026ndash;99\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMa Q et al (2024) Interactions between CNS and immune cells in tuberculous meningitis. Front Immunol 15:1326859\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMarais S et al (2014) Neutrophil-associated central nervous system inflammation in tuberculous meningitis immune reconstitution inflammatory syndrome. Clin Infect Dis 59:1638\u0026ndash;1647\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRuiz-Bedoya CA et al (2022) High-dose rifampin improves bactericidal activity without increased intracerebral inflammation in animal models of tuberculous meningitis. J Clin Invest 132\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMota F et al (2022) Dynamic (18)F-Pretomanid PET imaging in animal models of TB meningitis and human studies. Nat Commun 13:7974\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eChen X et al (2024) Dynamic PET reveals compartmentalized brain and lung tissue antibiotic exposures of tuberculosis drugs. Nat Commun 15:6657\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSoria J et al (2019) Mortality in hospitalized patients with tuberculous meningitis. BMC Infect Dis 19:9\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eJaipuriar RS et al (2019) Early Mortality among Immunocompetent Patients of Tuberculous Meningitis: A Prospective Study. Am J Trop Med Hyg 101:357\u0026ndash;361\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBhaskar A et al (2020) Host sirtuin 2 as an immunotherapeutic target against tuberculosis. Elife 9\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSubbian S et al (2011) Phosphodiesterase-4 inhibition alters gene expression and improves isoniazid-mediated clearance of Mycobacterium tuberculosis in rabbit lungs. PLoS Pathog 7:e1002262\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eThwaites GE et al (2004) Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med 351:1741\u0026ndash;1751\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSingh M et al (2025) Proapoptotic Bcl-2 inhibitor as potential host directed therapy for pulmonary tuberculosis. Nat Commun 16:3003\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWang JY et al (2016) Pomalidomide mitigates neuronal loss, neuroinflammation, and behavioral impairments induced by traumatic brain injury in rat. J Neuroinflammation 13:168\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHanlon DP, Gale TF, Ferm VH (1975) Permeability of the syrian hamster placenta to manganous ions during early embryogenesis. J Reprod Fertil 44:109\u0026ndash;112\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBerk M et al (2013) Aspirin: a review of its neurobiological properties and therapeutic potential for mental illness. BMC Med 11:74\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMichael J et al (2021) The Leukotriene Receptor Antagonist Montelukast Attenuates Neuroinflammation and Affects Cognition in Transgenic 5xFAD Mice. Int J Mol Sci 22\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHeye AK, Culling RD, Hernandez Mdel V, Thrippleton C, M.J., Wardlaw JM (2014) Assessment of blood-brain barrier disruption using dynamic contrast-enhanced MRI. A systematic review. Neuroimage Clin 6:262\u0026ndash;274\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBaran AI et al (2023) Evaluation of cerebrospinal fluid levels for ALOX5, S100B, DEFA1, and GFAP in infectious meningitis. Med (Baltim) 102:e36463\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRohlwink UK et al (2017) Biomarkers of Cerebral Injury and Inflammation in Pediatric Tuberculous Meningitis. Clin Infect Dis 65:1298\u0026ndash;1307\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eTe Brake L et al (2015) Pharmacokinetic/pharmacodynamic analysis of an intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis. Int J Antimicrob Agents 45:496\u0026ndash;503\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHeemskerk AD et al (2016) Intensified Antituberculosis Therapy in Adults with Tuberculous Meningitis. N Engl J Med 374:124\u0026ndash;134\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKim J, Koo BK, Knoblich JA (2020) Human organoids: model systems for human biology and medicine. Nat Rev Mol Cell Biol 21:571\u0026ndash;584\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eQian X, Song H, Ming GL (2019) Brain organoids: advances, applications and challenges. Development 146\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCatalizing the Development and Use of Novel Alternative Methods (2023) Advisory Committee to the Director, National Institutes of Health\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBolton AE et al (2004) Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects. Cancer Chemother Pharmacol 53:102\u0026ndash;106\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eShee S et al (2025) Elimination of senescent cells with senolytic host-directed therapy reduces tuberculosis progression in mice. bioRxiv\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWallis RS et al (2021) Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial. Lancet Respir Med 9:897\u0026ndash;908\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKrug S et al (2023) Inhibition of host PARP1 contributes to the anti-inflammatory and antitubercular activity of pyrazinamide. Nat Commun 14:8161\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSchoeman JF et al (2004) Adjunctive thalidomide therapy for childhood tuberculous meningitis: results of a randomized study. J Child Neurol 19:250\u0026ndash;257\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDavis AG, Wilkinson RJ (2021) Aspirin in tuberculous meningitis. EClinicalMedicine 35:100871\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAslanian D, Negrerie M (1985) A Raman spectroscopic investigation of the lipid state in acetylcholine receptor-rich membranes from Torpedo marmorata. EMBO J 4:965\u0026ndash;969\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMai NTH et al (2018) A randomised double blind placebo controlled phase 2 trial of adjunctive aspirin for tuberculous meningitis in HIV-uninfected adults. Elife 7\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMarais BJ et al (2021) Use of Infliximab to Treat Paradoxical Tuberculous Meningitis Reactions. Open Forum Infect Dis 8:ofaa604\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHardwick C et al (2006) Montelukast in the treatment of HIV associated immune reconstitution disease. Sex Transm Infect 82:513\u0026ndash;514\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCalderin JM et al (2025) Pharmacokinetics of Dexamethasone in Tuberculous Meningitis. Clin Infect Dis\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eNassr N et al (2009) Effects of rifampicin on the pharmacokinetics of roflumilast and roflumilast N-oxide in healthy subjects. Br J Clin Pharmacol 68:580\u0026ndash;587\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eChen X et al (2026) Beyond Rifampin: Evaluating Rifapentine and Rifabutin as Alternative Treatments for TB Meningitis. J Infect Dis\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eFang H et al (2025), \u003cem\u003eAPOE genotype confers context-dependent neurovascular vulnerability in immune-vascularized human forebrain organoids. bioRxiv\u003c/em\u003e\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":true,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"nature-portfolio","isNatureJournal":true,"hasQc":false,"allowDirectSubmit":false,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"","title":"Nature Portfolio","twitterHandle":"","acdcEnabled":false,"dfaEnabled":false,"editorialSystem":"ejp","reportingPortfolio":"","inReviewEnabled":true,"inReviewRevisionsEnabled":false},"keywords":"","lastPublishedDoi":"10.21203/rs.3.rs-8694483/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-8694483/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003eTuberculous meningitis (TB meningitis) is a major cause of death and neurological deficit despite recommended antibiotic and corticosteroid treatments, primarily due to dysregulated neuroinflammation. Here, we investigate a diverse panel of 12 immunomodulatory drugs as host-directed treatments (HDTs) for TB meningitis utilizing a cross-species framework comprising studies in a mouse model of TB meningitis with clinical endpoints, and parallel mechanistic studies in a newly developed immune-vascularized human brain organoid model of TB meningitis and peripheral blood mononuclear cells (PBMCs) from patients with TB meningitis. We identify new HDTs that outperform the current standard of care by reducing mortality and neurological deficits in mice via suppression of neuroinflammation. Importantly, these HDTs significantly reduce microglial activation in \u003cem\u003eMycobacterium tuberculosis\u003c/em\u003e-infected human brain organoids and attenuate proinflammatory cytokines, particularly IFNγ within CD4\u0026thinsp;+\u0026thinsp;T-cells in patient-derived PBMCs. These findings highlight the potential of targeted HDTs to improve outcomes in TB meningitis and warrant clinical investigation.\u003c/p\u003e","manuscriptTitle":"Host-directed treatments for tuberculous meningitis: A multi-platform approach across mouse and human models","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2026-03-08 17:12:56","doi":"10.21203/rs.3.rs-8694483/v1","editorialEvents":[],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"nature-communications","isNatureJournal":true,"hasQc":false,"allowDirectSubmit":false,"externalIdentity":"NCOMMS","sideBox":"Learn more about [Nature Communications](http://www.nature.com/ncomms/)","snPcode":"","submissionUrl":"https://mts-ncomms.nature.com/","title":"Nature Communications","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"ejp","reportingPortfolio":"Nature Communications","inReviewEnabled":true,"inReviewRevisionsEnabled":false}}],"origin":"","ownerIdentity":"5ce2c77f-80e1-4748-baaa-dc0381bffb05","owner":[],"postedDate":"March 8th, 2026","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"under-review","subjectAreas":[{"id":63937438,"name":"Health sciences/Medical research/Translational research"},{"id":63937439,"name":"Health sciences/Pathogenesis/Infection"},{"id":63937440,"name":"Health sciences/Medical research/Experimental models of disease"}],"tags":[],"updatedAt":"2026-04-15T22:55:20+00:00","versionOfRecord":[],"versionCreatedAt":"2026-03-08 17:12:56","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-8694483","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-8694483","identity":"rs-8694483","version":["v1"]},"buildId":"XKTyCvWXoU3ODBz1xrDgd","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}